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Abstract 
 DEM30355/A 1 is a novel bioactive natural product polyketide isolated from an 
Amycolatopsis bacteria. 1 shows antibacterial activity against several pathogenic Gram 
positive bacteria, including methicillin-resistant Staphylococcus aureus. Thus we have 
explored the total synthesis of 1 and a number of related polyketide natural products 
(Figure 1). 
 
Figure 1: Structure of DEM30355A 1. 
 In our first attempts towards the synthesis of target molecule 1 we examined several 
synthetic routes towards a key intermediate 2. These routes included: (a) the synthesis of 
Wittig product 3, followed by an unsuccessful attempt at a sterically challenging Baylis-
Hillman reaction with diethyl ketomalonate 4; (b) following the synthesis of 5, an attempted 
Lewis acid catalysed Friedel-Crafts reaction between 1,4-dimethoxybenzene 6 and 5; and 
(c) Heck coupling of 2-bromo-1,4-dimethoxybenzene 8 with 5. The best results were 
obtained via route (c) although the yields from the Heck coupling were low, prompting us 
to examine an alternative route (Scheme 1). 
Scheme 1: Examined routes to key synthetic intermediate 2. 
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We then examined alternative synthetic approaches towards the aromatic ring A of 
target molecule 1, based on the formation of the synthetic intermediate 9. Compound 11, 
which contains the core substitution pattern needed to create ring A, was successfully 
produced via an unusual bromination of 2,5-dihydroxybenzaldehdye 10. After considerable 
optimisation we developed a method for the di-methylation of 11. Reduction of aldehyde 
12 into corresponding alcohol 13 and subsequent protection of 13 with TBDMSCl gave 14 
in a high yield. The synthesis of 9 was completed via a halogen-metal exchange reaction of 
14 followed by trapping with DMF (Scheme 2).  
 
Scheme 2: Synthesis of ring A. 
Alongside our work towards the synthesis of 1, we have examined the total 
synthesis of the polyketide natural product (-)-(3R)-5-hydroxymellein 15, starting from 
the previously synthesised common intermediate 13. We have successfully synthesised 
18, the deoxy-analogue of 15, via a halogen-metal exchange reaction of 16 followed by 
ring opening of propylene oxide and followed by deprotection and cyclisation. 
 Abstract 
 
 
iv 
 
 
Scheme 3: Progress towards the total synthesis of (-)-(3R)-5-hydroxymellein 15. 
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Chapter 1 
1. Introduction  
1.1. Bacterial Diseases and Resistance 
 Despite the availability of antibiotics, bacterial infections are still the second 
leading-cause of death, causing 17 million fatalities every year worldwide.1 In recent years, 
there has been a growing concern in society towards the increasing levels of resistance in 
bacteria and other microorganisms to antimicrobial agents. Infection caused by resistant 
pathogenic bacteria increases the mortality rate of infected patients as there are no effective 
treatments.2,3 Public Health England (PHE) agency reported in 2014 that antimicrobial 
resistance (AMR) is “one of the greatest threats we face today”4, whilst the World Health 
Organisation (WHO) warned in a report published on 2014 that the world is moving 
towards “post-antibiotic era” when minor injuries and ordinary infections can be fatal.5 The 
Centres for Disease Control and Prevention (CDC) have listed antibiotic resistance as a 
“worldwide problem that pose a catastrophic threat to people in every country in the 
world”3, and the World Economic Forum in 2014 classified bacterial resistance to antibiotic 
as a major global risk.6 
 The emerging threat of resistant pathogenic microbes is already leading to a 
decrease in positive patient outcomes. For instance, at least 2 million people in USA are 
infected with antibiotic resistant bacteria leading to 23,000 deaths per year, whilst the 
additional healthcare cost have been estimated at around $20 billion.3 In Europe, 400,000 
people suffer from infections caused by resistant bacteria, resulting in 25,000 deaths each 
year costing the healthcare systems in the European Union over €1.5 billion.7  
 In 2015, following PHE warnings, the National Risk Register of Civil Emergencies 
(NRR) in the UK classified AMR infections as a serious long-term risk, as the rate of 
resistant infections are expected to increase in the next 20 years. NRR claimed that if an 
outbreak of an antimicrobial resistant infections were to occur, nearly 200,000 people 
would be likely to be affected by bacterial blood infections (sepsis) that do not respond 
effectively to existing antibiotics and around 80,000 people could die.8 Currently, sepsis 
due to antimicrobial resistance affects 100,000 people in the UK, causing 36,800 deaths 
each year.9 
 Before proceeding to identify the origin and the mechanisms of antibiotic 
resistance, we will review the sources of existing antibiotic classes, with a focus on 
antibiotics from nature, and their mode of action. 
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1.2. Antibiotics 
1.2.1. Nature as a Source of Antibiotics 
It has been postulated that antibiotic producing microorganisms (bacteria and fungi) 
employ a form of chemical warfare to compete with neighbours for nutrition and space.10,11 
Many microorganisms have the ability to produce molecules which either kill (bactericidal) 
or slow the growth (bacteriostatic) of other bacteria. This gives a Darwinistic advantage to 
the producing microorganism allowing them to consuming nutrients from the defeated 
neighbor. Antibiotic producing bacteria can also regulate the production of secondary 
metabolites in response to environmental pressure (such as a decrease in available 
nutrients), turning on antibiotic producing pathways only when necessary.12,13 
 
1.2.2. Natural Products and Antibiotics Drug Discovery  
 Natural products have played an essential role in the discovery of antibiotics and 
are likely to remain a key source of new antibiotic lead molecules for the future.1,14 The 
majority of natural product-derived antibiotics are produced by bacteria and fungi. Of the 
antibiotic producing bacteria, most are actinomyces and streptomyces a genera of 
actinobacteria that exist in soil and marine environments. Of these naturally derived 
antibiotics, actinobacteria, Gram-positive (G-p) bacteria with high percentage of guanine 
and cytosine bases in their DNA, are a major source.15 Figure 1.1 illustrates the sources of 
new antibiotics approved for human use between 1981 and 2010 showing that a large 
proportion of clinically used antibiotics are derived from natural products.16 
 
Figure 1.1: New antibacterial agents approved between 1981-2010. 
 
Natural product 
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1.2.3. Antibiotics Isolated from Natural Sources  
There are five major classes of antibiotics that have been derived from natural 
sources, the β-lactams, aminoglycosides, tetracyclines, macrolides and streptogramins 
(Figure 1.2).17,18, 19,20 
 
 
 
Figure 1.2: Antibiotics isolated from nature. 
 These antibiotics target five key biological pathways in bacteria by disrupting cell 
wall biosynthesis, protein biosynthesis, DNA or RNA synthesis, folate biosynthesis or 
membrane integrity (Table 1.1). 17,18, 19,20 
 
Class Source Pharmacophore  Mode of Action 
β-lactams Penicillium 
notatum 
mould 
Four-membered β-
lactam ring. 
 
 
 
 
Inhibit cell wall biosynthesis 
of Gram-positive (G-p). 
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Aminoglycosides Streptomyces 
griseus 
Amino sugars linked by 
glycoside bonds. 
Broad-spectrum, first 
antibiotics that showed 
activity against Gram-
negative (G-n) bacteria, 
bactericidal, inhibit protein 
synthesis at a ribosomal level 
of G-p and G-n bacteria. 
Tetracyclines Streptomyces Polyketide antibiotics  
containing four fused 
six-membered rings. 
Inhibit protein synthesis at a 
ribosomal level of G-p and G-
n bacteria. 
Macrolides Streptomyces Polyketide antibiotics 
include 
macrocyclic lactone 
ring. 
Disrupt protein biosynthesis 
of G-p and 
 G-n bacteria. 
Streptogramins Streptomyces Include two structurally 
unrelated molecules: 
group A 
(macrolactones) and 
group B (cyclic 
hexadepsipeptides)  
Inhibit protein synthesis at the 
ribosomal level. 
Each molecule is 
bacteriostatic, however, a 
combination of the A and B is  
bactericidal. 
Table 1.1: Source, pharmacophore and mode of action of selected natural product antibiotics. 
 
1.2.4. Timeline of Antibiotic Discovery and New classes of antibiotics  
 However, from 1970 until recently only six new classes of antibacterial agents 
(mupirocins, oxazolidinones, lipopeptide daptomycin, mutilins, fidaxomicin and 
bedaquiline) were approved for use in humans.1,21,22,23 Therefore there is a need for novel 
antibiotics with new modes of action to be discovered to combat the current resistance to 
many of the existing classes of antibiotics.The following Figure 1.3 shows the timeline of 
the discovery of antibiotics from 1908 to 2012. 
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Figure 1.3: Timeline of Antibiotic discovery from 1908 to 2012. 
 
 More recently a number of new compounds are being researched as part of the 
strategy to overcome resistant infections. Thus in 2015, NovoBiotic Pharmaceuticals LLC 
announced the discovery of teixobactin, a new class of antibiotics which interfere with the 
lipid II pathway, isolated from a G-n soil bacterium, Eleftheria terrae. Teixobactin 1.6 is a 
depsipeptide made up of a number of modified amino acids, including enduracididine, 
methylphenylalanine, and four D-amino acids (Figure 1.4).24 
Figure 1.4: Chemical structure of teixobactin 1.6. 
 Teixobactin 1.6 shows remarkable antibiotic activity against G-p bacteria, including 
drug resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin resistant enterococci. Despite the fact that the producer of 1.6 antibiotic is a 
G-n bacterium, 1.6 shows no activity against most of G-n bacteria since it cannot penetrate 
the outer membrane. This was demonstrated by testing 1.6 on a strain of E. coli asmB1 with 
an impaired “leaky” outer membrane, against which teixobactin was active (Table 1.2).24 
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Species Teixobactin MIC μg/ml  
Clostridium difficile 0.005 
Staphylococcus aureus (MRSA) 0.25 
Enterococcus faecium (VRE) 0.5 
Escherichia coli 25 
Escherichia coli (asmB1) 2.5 
Table 1.2: The activity of teixobactin 1.6 antibiotic against pathogenic bacteria. 
 The mode of action of teixobactin involves in the inhibition of bacterial cell wall 
biosynthesis by binding to two cell wall components: lipid II (peptidoglycan) and lipid III 
(teichoic acid). No resistance has yet been observed from Staphylococcus aureus or 
Mycobacterium tuberculosis against teixobactin, thus this antibiotic shows promise for the 
future treatment of MDR G-p infections.24  
 
1.3. Antibiotic Resistance 
1.3.1. Origin of Antimicrobial and Antibiotic Resistance 
 Antimicrobial resistance refers to the ability of a pathogenic microbe (bacteria, 
fungi, virus or parasite) to survive in the presence of a drug used to kill or stop their 
growth.4,5 Antimicrobial resistance is a natural phenomenon caused by the application of 
Darwinistic selection pressure via an antibiotic on the microbe. Thus exposure of any 
microbial population to an antibiotic will, over time, lead to the generation of resistance. 
Antibiotic resistance increases as a consequence of antibiotic usage. Bacterial resistance to 
antibiotics has been observed in the clinic from as quickly as a few months to many years 
after the first use of an antibiotic (Table 1.3).23 
Antibiotics Year of Clinical Use Resistance Observed 
Sulfonamides 1930s 1940s 
Penicillin 1943 1946 
Streptomycin 1943 1959 
Chloramphenicol 1947 1959 
Tetracycline 1948 1953 
Erythromycin 1952 1988 
Vancomycin 1956 1988 
Methicillin 1960 1961 
Cephalosporins 1960s late 1960s 
Ampicillin 1961 1973 
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Nalidixic acid 1962 1962 
Fluoroquinolones 1980s 1980s 
Linezolid 1999 1999 
Daptomycin 2003 2003 
Retapamulin 2007 2007 
Fidaxomicin 2011 2011 
Bedaquiline late 2012 ? 
Table 1.3: Appearance of resistance to clinically used antibiotics. 
 
1.3.2. Genetic Mechanisms of Antibiotic Resistance 
 Bacterial resistance to antibiotics at the genetic level can be intrinsic or acquired 
and resistant traits can be transmitted by both vertically or horizontally. Vertical 
transmission involves offspring bacteria inheriting resistant genes from their parents, whilst 
horizontal transmission happens by directly transferring resistant genes from one bacterium 
to another within a population.25 
 
1.3.2.1 Intrinsic Resistance 
Some pathogenic bacteria are naturally resistant to specific classes of antibiotic due 
to poor penetration of the antibiotic into cellular bacteria or lack of reliance on an antibiotic 
target enzyme. For instance, vancomycin is a glycopeptide antibiotic that binds to 
D-Ala-D-Ala peptides and inhibits peptidoglycan crosslinking in the cell wall of most G-p 
bacteria. Whereas, G-n bacteria are intrinsically resistant to Vancomycin since the 
molecule cannot penetrate the outer membrane.26,27 
 
1.3.2.2 Acquired Resistance 
Much of the antibiotic resistance that occurs in pathogenic bacteria arises when 
bacteria acquire resistance genes. The increase in resistance genes can occur in several 
ways: 
 After exposure to an antibiotic and a period of bacterial growth, bacteria containing 
minor genetic variations, which improved their survival, are enriched in the 
resulting population. Over many iterations this leads to bacteria which have been 
preferentially selected to be the most resistant. Resistance genes can then be 
transmitted between bacteria by two means: vertical gene transfer (VGT) or 
horizontal gene transfer (HGT).25,28 
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 Vertical gene transfer (VGT): offspring bacteria inherit resistance genes from 
resistant parent bacteria during DNA replication. 28,29 
 Horizontal gene transfer (HGT): receiving antibiotic resistance gene from a 
neighboring resistant bacteria. HGT occurs via three mechanisms: 28,30 
a) Transformation: bacteria absorb “naked” DNA from dead bacteria in their 
environment and incorporate it into their own DNA. Donor and receiving bacteria 
are normally close to each other.  
b) Conjugation: transferring a plasmid (small circular part of DNA that carry 
antibiotic resistance and other genes) via direct contact between the cell walls of 
the donor and recipient bacteria. 
c) Transduction: transferring resistant DNA from one bacterium to another by a virus 
called bacteriophage, which can lead to transmission of a resistant gene over a long 
distance.  
 
Antibiotic resistance genes of this type usually exist in a small piece of DNA called 
a transposon. Some transposons include a complex DNA fragment known as an “integron” 
that exist in both G-p and G-n bacteria. Integrons significantly contribute in the evolution 
of multidrug resistance bacteria since they can carry several antibiotic resistance genes at 
one time.28,30 
 
1.3.3. Biological Mechanisms of Antibiotic Resistance 
 After mutation or gene transfer, antibiotic resistance arises when biological 
modifications in bacterial cell interrupt the activity of the antibiotic. There are several main 
biological mechanisms of antibiotic resistance (Figure 1.5). 28,31 
 Efflux: bacteria develop active or passive transport mechanisms to pump antibiotic 
molecules outside the cell until the concentration of the antibiotic becomes low 
enough to be tolerated by the bacteria. Efflux strategies have been used by bacteria 
against the β-lactams, tetracyclines, macrolides and fluoroquinolones.32 
 Target modification: bacteria change the target of an antibiotic to reduce the 
antibiotic binding affinity. This includes the cell wall biosynthesis, and DNA 
replication proteins and the ribonucleoprotein complex of the ribosome.30 For 
example, bacteria become resistant to aminoglycoside through ribosomal 
alteration.28 
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 Inactivating enzymes: bacteria produce one or more enzymes that modify, destroy 
or chemically degrade the antibiotic. A well-known example are the β-lactamase 
enzymes that are produced to hydrolyze β-lactam antibiotics.26 
 Bypass: by-passing the metabolic pathway targeted by antibiotics.31 
 Immunity: antibiotic or its target binds to a second protein to interrupt antibiotic-
target binding process.31,33 
 Cell membrane/wall: decreasing the permeability of the cell wall towards the 
antibiotic.34 
 Overproduction: producing more of the enzyme targeted by antibiotic. For example 
the chromosomal AmpC enzyme can be overproduced by mutant Pseudomonas G-
n bacteria, increasing the resistance to most β-lactam antibiotics.35 
 
Figure 1.5: Antibiotics mode of action and antibiotic resistance pathways in bacterial cell. 
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1.3.4. Superbugs and Multidrug Resistance 
Superbugs are strains of infectious bacteria demonstrating extreme resistance to 
multiple antibiotics due to multiple mutations, ultimately leading to poor patient outcomes. 
Multidrug resistant bacteria display resistance to most available antibiotic classes, 
particularly those antibiotics used frequently in the clinic.36 Multidrug resistant infectious 
G-p and G-n bacteria can cause life-threatening infections, both community and hospital 
acquired, in developed and developing countries. This group includes Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, 
Pseudomonas aeruginosa, and Enterobacter species, the ESKAPE pathogens.37 
 
 Pathogenic multi-drug resistant bacteria also include Mycobacterium tuberculosis that 
causes multi-drug resistance tuberculosis (MDR-TB) and methicillin-resistant 
Staphylococcus aureus (MRSA) The following case studies highlight recent data about 
MDR-TB and MRSA morbidity, mortality and available treatments. 
 
1.3.5. Antibiotic Resistant Mycobacterium tuberculosis (MDR-TB and XDR-TB) 
 Tuberculosis (TB) is a very commonly occurring infectious disease is caused by 
Gram-positive bacteria Mycobacterium tuberculosis. TB is contagious and air transmitted 
and mostly affects the lungs. According to WHO, one-third of the world’s population is 
infected with TB.38 It is estimated that 49 people become ill and nearly 7 patients die every 
hour in Europe because of TB.39 Globally, TB affects around 9 million people, causing 1.4 
million deaths in 2013. Despite this, drug susceptible TB is a curable disease.38 Standard 
treatment for TB consists of a combination of four oral antibiotics (isoniazid 1.7, rifampicin 
1.8, pyrazinamide 1.9 and ethambutol 1.10) for 6 months divided into two stages. The first 
stage of treatment is called “intensive phase” as it includes all four antibiotics for the first 
two months. The second stage includes rifampicin and isoniazid for the following four 
months. If the treatment procedure is supervised directly by a healthcare provider, the cure 
rate from TB is above 95% (Figure 1.6).40 
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Figure 1.6: Chemical structures of antibiotics used as a first line treatment for TB. 
 
 If the TB infection has not been treated properly, Mycobacterium tuberculosis can 
develop a mechanism to resist rifampicin and isoniazid to produce a severe form of TB 
called Multidrug-resistant TB (MDR-TB).40 In 2013, there were around 480,000 new cases 
of multidrug resistant TB (MDR-TB) and around 210,000 patients died worldwide.41 
Second-line treatment is recommended to fight MDR-TB infection for at least 20 months, 
the therapy consist of three main groups of oral and injectable antibiotics:40 
Group 1) IV aminoglycosides: streptomycin, kanamycin, amikacin and IV polypeptides: 
capreomycin, viomycin.  
Group 2) Oral and IV fluoroquinolones: ciprofloxacin, levofloxacin, moxifloxacin, 
ofloxacin, gatifloxacin.  
Group 3) Oral: para-aminosalicylic acid, cycloserine, terizidone, ethionamide, 
prothionamide, thioacetazone, linezolid. 
 Although second line treatment proves effective for many patients, Mycobacterium 
tuberculosis strains have since developed with resistance to first and second line treatments. 
In 2006 extensively multidrug resistance TB (XDR-TB) was first reported, involving the 
discovery of TB strains that displays resistance to rifampicin, isoniazid, fluoroquinolones 
and at least one of the three injectable second-line drugs: amikacin, kanamycin and 
capreomycin.40 Therefore, there is a critical need for new antibiotics capable of overcoming 
the MDR-TB and XDR-TB Infections. 
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1.3.6. Methicillin-resistant Staphylococcus aureus (MRSA) 
 S. aureus can causes serious problems in hospitals particularly in patients with 
surgical wounds.12 MRSA infects around 50 million individuals worldwide every year.42 
According to CDC, around 80,461 patients suffered from severe MRSA infections and an 
estimated 11,285 deaths in 2011in the USA.3 Penicillins including methicillin are the first 
line treatment for S. aureus infection. However MRSA is resistant to all the penicillins. 
Vancomycin and linezolid have been used to treat MRSA infected patients. However 
MRSA strains have recently been discovered exhibiting multidrug resistance against both 
vancomycin 1.11 and the linezolid 1.12 antibiotics (Figure 1.7).43,44 
 
Figure 1.7: Chemical structures of most common antibiotics used to treat MRSA infection. 
 
1.4. Conclusions 
 Thus antimicrobial agents that in the past might have been effective against 
bacterial infection become far less effective against increasingly resistant strains. Not only 
does resistance evolve slowly through classical evolutional selection, horizontal gene 
transfer can lead to the appearance of a resistant infectious agent very rapidly. As existing 
antibiotics therefore became ineffective, along with improved management of antibiotic 
use, there is a significant need for research to focus on new mode of action antibiotics that 
can overcome resistant pathogens. If the antimicrobial resistance remains uncontrolled it 
has been estimated by 2050 there will be an additional 10 million deaths worldwide.45 
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1.5. Polyketides  
 Polyketides are a class of secondary metabolites that are produced by 
microorganisms (bacteria and fungi) and plants. Several polyketide natural products are 
therapeutically useful as antibiotics and anticancer agents. Doxorubicin 1.13 is an 
anthracycline antibiotic, and is used widely as a cancer chemotherapy treatment, whilst 
tetracyclines are a well-known family of broad spectrum antibiotics that are effective in the 
treatment of a wide range of bacterial infections.46,47,48 Although the total chemical 
synthesis of natural product polyketides is highly challenging, gaining an understanding of 
both their structure and their therapeutic effect are the motivation for researchers to explore 
the synthesis and biosynthesis of natural product polyketides (Figure 1.8).49 
 
Figure 1.8: Chemical structure of doxorubicin 1.13. 
 
1.5.1. The Biosynthesis of Natural Product Polyketide  
 The biosynthesis of polyketides has many similarities to fatty acid biosynthesis, 
involving two carbon chain elongation steps, oxidation changes and common building 
blocks (e.g. acetyl coenzyme A and malonyl coenzyme A).  
 In the biosynthesis of both fatty acids and polyketides, the starter unit is attached to 
a cysteine thiol of a ketosynthase enzyme (KS). The extender unit is then loaded on to a 
cysteine thiol of an acyl carrier protein (ACP), by an acyl transferase (AT) or malonyl acyl 
transferase (MAT). 
 In fatty acid biosynthesis, acetyl-CoA is the starter unit for chain initiation followed 
by malonyl-CoA as the extender unit for chain elongation. In contrast, a range of acyl 
groups can be involved in polyketide biosynthesis including acetyl-, malonyl-, malonamyl-
, propionyl-, butyryl-, cyclohexyl-, benzoyl- and 3-hydroxy-5-amino benzoyl-CoA as 
starter units while, malonyl-CoA and methylmalonyl-CoA are employed as the extender 
units (Figure 1.9).47,48,12 
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Figure 1.9: Building blocks for (A) initiation and (B) elongation cycles by PKS assembly lines.12 
 
 Fatty acids are formed by repetitive decarboxylative Claisen thioester condensation 
of an activated starter unit with an extender unit. After the chain elongation step several 
other enzymes are involved, ketoreductase (KR) introduces the β-oxo functional group, 
dehydrates (DH) and enoyl reductase (ER) to produce a saturated acyl backbone (Scheme 
1.1).47,48,12 
 
Scheme 1.1: General mechanism for fatty acid biosynthesis.12,49 
 
 In contrast, in the polyketide biosynthesis more complex molecules can be produced 
as the chain elongation steps can be followed by many different combinations of 
enzymatically catalysed reactions (KR, DH, ER and others) as well as non-enzymatic 
reactions (Scheme 1.2).47,48,12 
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Scheme 1.2: General mechanism for polyketides biosynthesis.12,49 
 
1.6. Conclusions 
 Due to the potential for variation in the biosynthetic pathways for polyketide 
biosynthesis, a high variety of different complex molecular structures can be generated. 
These natural product polyketides from bacteria and other microorganisms are thus a 
valuable resource for the discovery of new antibiotics.  
 
1.7. Project Background 
 The aim of this thesis was to explore the total synthesis of DEM30355/A 1.14 and 
a number of related polyketides. DEM30355/A 1.14 is a novel bioactive compound 
discovered in Newcastle which displays G-p antibiotic activity, with a mode of action 
which whilst unknown appears to be different compared to existing clinically used 
antibiotics. DEM30355/A 1.14 was isolated from an Amycolatopsis strain by Demuris Ltd., 
a Newcastle University spin out company focused on the discovery of novel antibiotics. 
DEM30355/A 1.14 is a fluorescent polyketide natural product with a high content of 
oxygen atoms. The complexity of 1.14 arises from its chemical structure which includes 
five contiguous stereocenters with one distinct five membered lactone ring and three 
different six membered rings: one aromatic ring,saturated and partially saturated rings. The 
structure of 1.14 was confirmed by NMR and single crystal X-ray analysis (Figure 1.10). 
Chapter 1   Introduction 
 
 
16 
 
 
Figure 1.10: X-ray crystal structure of DEM30355/A 1.14. 
 The antibiotic activity of DEM30355/A 1.14 was examined against different 
pathogenic G-p and G-n bacteria, and it shows remarkable activity only against a range of 
G-p bacteria, in particular methicillin-resistant Staphylococcus aureus (Table 1.4). 
Species DEM30355/A 
S. aureus 8 
S. pneumoniae 8 
E. faecium 16 
E. coli >128 
Table 1.4: MIC of DEM30355/A 1.1 against different pathogenic bacteria. 
 
 DEM30355/A 1.14 has some structural similarities to the rishirilides, in particular 
rishirilide A 1.15 (Figure 1.11).  
 
Figure 1.11: Structures of DEM30355/A 1.14 and rishirilide A 1.15. 
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1.8. Rishirilides  
 (+)-Rishirilide A 1.15 and (+)-rishirilide B 1.16 were isolated by Iwaki and co-
workers from Streptomyces rishiriensis OFR-1056 in 1984, they act as 𝛼2-macroglobulin 
inhibitors but neither have been reported as having any significant antibiotic activity.50 
Rishirilide B 1.16 shows higher activity in inhibiting 𝛼2-macroglobulin with an IC50 = 35 
μg/ml, while rishirilide A 1.15 shows weaker inhibition with IC50 = 100 μg/ml.51 The 
biological activity of rishirilide B 1.16 was further examined and it was classified as a 
glutathione S transferase inhibitor with an IC50= 26.9 μM.52 Thus 1.16 could be useful in 
treating cancer since glutathione S transferase increases resistance against anticancer drugs. 
In 2012, the first cloning of the type II PKS biosynthetic gene cluster (rsl.) from 
Streptomyces bottropensis was carried out by A. Yan, K. Probst, A. Linnenbrink, M. 
Arnold, T. Paululat, A. Zeeck and A. Bechthold to produce 1.15 and 1.16 and to study the 
biosynthesis(Figure 1.12).51 
 
Figure 1.12: Structures of (+) rishirilide B 1.16. 
  
1.8.1. The Biosynthesis of Rishirilides A and B  
 The biosynthesis of rishirilides A 1.15 and B 1.16 includes the formation of 
rishirilide B 1.16 first, which is hypothesized to be the precursor for rishirilide A 1.15 
(Scheme 1.3).53 
The biosynthesis of rishirilide B 1.16 involves: 
1) Iterative condensation reactions (8 elongation cycles) between a branched starter unit 
and several malonyl-CoA or malonyl-ACP extender unit catalysed by RslK1, RslK3 
and related PKS enzymes to yield the full length polyketide backbone.  
2) RslO10 catalysed the reduction reaction of ketone at C-9 to introduce a hydroxyl 
group followed by ring closure at C-7 and C12. 
3) The resulting ring aromatises under the control of RslC1 to form the first aromatic 
ring. 
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4) A Favorskii rearrangement, catalysed by luciferase-like monooxygenase enzymes 
(RslO1) and (RslO2), introduces an oxygen atom at C-16 to form a reactive 
intermediate followed by the migration of the isopentyl group from C-18 to C-15. Then 
hydroxyl and carboxyl groups were formed at C-16 at C-17 respectively. 
5) The anthracene skeleton of the rishirilides is formed after cyclisation of the second and 
third rings catalysed by RslC2 and RslC3 respectively. Next, rishirilide B 1.16 is 
formed after tailoring reactions mediated by several oxidoreductases reactions such as 
RslO4, RslO7, RslO8 and RslO9. 
 The biosynthesis of rishirilide A 1.15 from rishirilide B 1.16 occurs in two steps: 
1) Epoxidation of rishirilide B 1.16 catalyses by RslO6, a luciferase-like monooxygenase 
enzyme. 
2) Lactone ring is then formed spontaneously (or possibly assisted by RslH), to generate 
rishirilide A 1.15.  
Scheme 1.3: Proposed biosynthetic pathway for rishirilides A 1.15 and B 1.16. 
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1.8.2. The Total Synthesis of Rishirilide B  
Due to the interesting biological activity of rishirilide B 1.16 as a small molecule 
anticlotting factor and anticancer agent, and in order to solve the absolute stereochemistry, 
several total syntheses have been published. 
 
1.8.2.1. Danishefsky Approach 
 The first total synthesis of racemic rishirilide B 1.16 was achieved by S. 
Danishefsky and J. Allen in 2001. The key step includes regioselective Diels–Alder 
reaction of quinodimethide 1.17 and enedione 1.18 to form 1.19 which represents the core 
structure of rishirilide B 1.16. Next, a series of chemical modification reactions such as 
deprotections, dehydration, aromatisation and a Grignard addition were performed to give 
(±) rishirilide B 1.16 as a racemic mixture in a 47% yield from the dienophile 1.18 (Scheme 
1.4).54 
 
Scheme 1.4: Synthesis of racemic (±) rishirilide B by Danishefsky. 
 Danishefsky and co-workers revisited the synthesis of rishirilide B, using 
enantiomerically pure dienophile 1.22 in order to access an entantiopure sample of the 
natural product for comparison. Completion of the synthesis following the original racemic 
procedure, gave rishirilide B as a single enantiomer. However, the resulting enantiomer 
turned out to be the unnatural (-) rishirilide B 1.23 (Scheme 1.5).55 
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Scheme 1.5: Synthesis of unnatural (-) rishirilide B 1.23. 
 
1.8.2.2. Pettus Approach 
 The total synthesis of (+)-rishirilide B 1.16 as it is found in nature was successfully 
achieved by T. Pettus and L. Mejorado in 2006. They have developed a synthetic route to 
1.16 based on producing anthracene (-)-1.26, the skeleton of (+)-rishirilide B 1.16, via a 
Diels-Alder cycloaddition reaction of the enantiopure dienophile 1.25 to the diene derived 
from a cyclic sulfone 1.24 in the presence of DDQ. 
Scheme 1.6: Total synthesis of (+) rishirilide B 1.16 by Pettus. 
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The cleavage of lactone ring from the resulting anthracene 1.26 yielded 1.27. Next, 
selective O-acylation of the dione 1.27 with diethylcarbamyl chloride in the presence of 
Hünig's base produced 1.28. The excess addition of lithiated ethyl vinyl ether to the ketone 
1.28 lead to the formation of the enolate 1.29. Work-up of 1.29 with saturated solution of 
NaCl followed by an epoxidation with DMDO gave -hydroxy ketone (-)-1.30 in a high 
yield. The aldehyde 1.31 was afforded after reducing `-dihydroxy ketone 1.30 by 
sodium triacetoxyborohydrideto followed by oxidizing the resulting tetrol with NaIO4. The 
aldehyde 1.31 was converted into desired carboxylic acid 1.32 via NaOCl. At the final step 
the cleavage of the benzyl protecting group using palladium over carbon catalyst under 
hydrogen atmosphere gave (+)-rishirilide B 1.16 in 20% (Scheme 1.6).56 
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Chapter 2 
2. Results and Discussions 
2.1. Project Aims 
Due to the interest in developing new antibiotic molecules the aim of this project 
was to examine synthetic approaches to DEM30355/A 1.14 and related polyketides. 
 
2.2. Retrosynthesis of DEM30355/A 1.14 
 We have considered two different approaches towards the total synthesis of 
DEM30355A 1.14. These approaches focus on constructing the carbon skeleton of both 
rings A and B through an intramolecular cyclisation reaction of ring B. We envisioned that 
an intramolecular cyclisation to give ring B could be achieved through: 
i. A Friedel-Crafts (F-C) acylation approach. 
ii. An Aldol condensation approach.  
 Once we can develop a route to allow access to rings A and B we would develop 
this intermediate to include the synthesis of rings C and D. Therefore the retrosynthetic 
analysis of DEM30355A 1.14 including the ring C and D will be discussed in detail later. 
 
2.2.1. Friedel-Crafts Acylation Approach 
 In this strategy we aim to form ring B in compound 2.1 through an intramolecular 
F-C reaction between the electron rich aromatic ring A and a tethered activated carbonyl 
group in 2.2. In turn 2.2 could be produced from a Heck cross coupling reaction between 
2-bromo-1,4-dimethoxybenzene 2.3 and Baylis–Hillman adduct 2.4 (Scheme 2.1). 
 
Scheme 2.1: Proposed retrosynthetic approach to .14 via an intramolecular F-C reaction. 
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2.2.2. Aldol Condensation Approach 
 This approach is based on the formation of two bonds between an aromatic ring A, 
with a 1,2,3,4-subsitution pattern, and a suitably functionalised ring C in order to form ring 
B. Therefore ring B in compound 2.5 could be formed through an intramolecular Aldol 
condensation between the aldehyde and ketone in 2.6. Further disconnection between ring 
A and C in compound 2.6 gives the aldehyde 2.7 and an organometallic 2.8. Thus the 
coupling between ring A and C could be achieved through a nucleophilic addition of an 
organometallic 2.8 to aldehyde 2.7 via Barbier or Grignard type reaction, with a metal such 
as magnesium, zinc, indium or barium, to from the secondary alcohol 2.6 followed by 
cyclization of 2.6 to form 2.5 via an intramolecular aldol condensation (Scheme 2.2). 
Scheme 2.2: Proposed retrosynthetic approach to 1.14 via an intramolecular Aldol condensation. 
 
 In this chapter the retrosynthesis of DEM30355A 1.14 via intramolecular Friedel-
Crafts acylation approach will be discussed in detail. 
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2.3. Retrosynthetic Analysis of DEM30355/A 1.14 Based on an Intramolecular 
Friedel-Crafts Acylation Approach 
 We envisioned that our target molecule DEM30355/A 1.14 could be prepared via 
an intramolecular pinacol coupling of 2.9 followed by alcohol deprotection. Deprotonation 
of -hydrogen in 2.10 would produce the corresponding nucleophilic enolate which can 
undergo an intramolecular Claisen condensation reaction to give the n  cyclic lactone 2.9. 
Compound 2.10 could be obtained through the esterification of alcohol 2.11 with oxalyl 
chloride. The tertiary alcohol 2.11 could be produced by removing MOM protecting group 
from compound 2.12. Next the conversion of ester in compound 2.14 to an N-methoxy-N-
methylamide gives 2.13, allowing the addition of cis-propenyllithium to give 2.12. 
Stereoselective reduction of the prochiral ketone 2.15 using Zn(BH4)2 followed by 
protection of the resulting secondary alcohol with tert-butyldimethylsilyl chloride 
(TBDMSCl) would provide compound 2.14. The chelation directed reduction with 
Zn(BH4)2 is used to set the desired relative anti-stereochemistry between the resulting two 
protected alcohol groups. Next, the protection of the keto group in -unsaturated ketone 
2.16 as a cyclic acetal is essential to prevent any side reactions during the subsequent ketone 
reduction. Also due to the reactivity of hydroxyl groups, the protection of tertiary alcohol 
as a methoxymethyl acetal (MOM) is necessary, thus a double protection to give the 
compound 2.15 is envisaged. Then compound 2.17 could undergo cyclisation through 
intramolecular Friedel-Crafts acylation in the presence of a Lewis acid to from the ketone 
2.16. Compound 2.16 includes the skeleton for both rings A and B and introduces the first 
stereogenic centre, at the tertiary alcohol. Compound 2.17 would be produced through a 
Heck cross coupling reaction between the commercially available 2-bromo-1,4-
dimethoxybenzene 2.3 and the Baylis-Hillman adduct 2.18. Baylis-Hillman adduct 2.18 
could be produced through the Baylis-Hillman reaction of methyl vinyl ketone 2.19 and 
diethyl ketomalonate 2.20 (Scheme 2.3). 
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Scheme 2.3: Retrosynthesis of DEM30355/A 1.14 following intramolecular Friedel-Crafts acylation 
approach. 
  
Chapter 2 Studies towards The Total Synthesis of DEM30355/A 1.14 via a 
Friedel-Crafts Approach 
 
 
26 
 
2.4. Synthesis of Ring A and B: Synthesis of 2.16 via an Intramolecular Friedel-
Crafts Acylation  
 Therefore our first challenge was to investigate a Baylis-Hillman approach to 2.18 
as a key starting material in our proposed synthesis. 
 
2.4.1. Baylis-Hillman Reaction 
 Baylis-Hillman reaction is a useful method to form a single C-C bond at the -
position of unsaturated carbonyl compounds or their derivatives (esters and amides) 
and aldehydes or ketones, in the presence of a tertiary amine as a nucleophilic catalyst such 
as DABCO and DBU, to give highly functionalised products.57,58 Early example of this 
type of reaction was reported by K. Mortia in 1968 when methyl acrylate 2.22 reacted with 
acetaldehyde 2.21 in the presence of tricyclohexylphosphine gave hydroxylated product 
2.23.59 In 1972, A.B Baylis and M. D. Hillman optimised the Mortia reaction conditions by 
using DABCO as a catalyst (Scheme 2.4). 
 
Scheme 2.4: First reaction reported by A. Baylis and D. Hillman for functionalizing the position of 
an activated alkene 2.22. 
 The Baylis-Hillman reaction is widely employed in the total synthesis of many 
natural products to produce densely functionalized intermediates. For example, Corey and 
his co-workers developed an efficient stereoselective total synthesis of the anticancer agent 
Salinosporamide A 2.24 by applying the intramolecular Baylis-Hilman reaction to a 
ketoamide in the presence of quinuclidine (Scheme 2.5).60 
Scheme 2.5: Synthesis of the natural product Salinosporamide A 2.24 via an intramolecular Baylis-
Hillman reaction. 
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However, the major disadvantage of Baylis-Hillman reaction is the slow rate of 
reaction as it can takes several days or weeks.58  
 
2.4.2. Synthesis of Diethyl 2-hydroxy-2-(3-oxobut-1-en-2-yl)malonate 2.18 via a 
Baylis-Hillman Reaction 
 Based on a literature procedure, the preparation of 2.18 was examined by treating 
methyl vinyl ketone 2.19 solution in THF with diethyl ketomalonate 2.20 in the presence 
of 10% of DABCO catalyst at room temperature.61 
 
Scheme 2.6: Synthesis of 2.18 via a Baylis-Hillman reaction. 
 
 In our first attempt the reaction was worked up after 45 minutes, no change could 
be observed by TLC under UV light. However the 1H NMR of the crude product showed 
the presence of new signals corresponding to a terminal alkene. Therefore, we subjected 
the crude product to column chromatography to isolate the desired product 2.18, 
unfortunately the isolated yield was low 8%. Therefore, it was decided to increase the 
reaction time, in addition we investigated staining of the TLC plates with vanillin as this 
allowed us to observe the formation of the product in this reaction. We therefore repeated 
the reaction, monitoring by TLC and 1H NMR. After 24 hours the reaction was worked up 
and the crude 1H NMR showed that the yield of the product 2.18 increased significantly, 
estimated by integration to be approximately 65%. The product 2.18 was purified by 
column chromatography giving an isolated yield of 40%. We postulated that the low 
isolated yield was because of the decomposition of 2.18 on the column, therefore we 
decided to examine increasing the reaction time to increase the yield. Given a sufficiently 
high yield chromatography would then become unnecessary. Therefore, we repeated the 
reaction again. After 4 days at room temperature the product 2.18 was successfully formed 
in an excellent yield 98% with no purification required (Table 2.1 and Figure 2.1). 
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No. Reaction Time %Yield 
1 45 min 8* 
2 1 day 40* 
3 4 days 98 
*Isolated yield of the product 2.18 after column purification.  
Table 2.1: Yield optimisation in the formation of B-H product 2.18 
 
Figure 2.1: The formation of 2.18 against time by 1H NMR of the crude reaction mixtures. Distinctive 
terminal alkene signals of 2.18 are highlighted. 
 
2.4.3. Heck Coupling of Baylis-Hillman Adduct 2.18 and 2-Bromo-1,4-
dimethoxybenzene 2.3 
 The Heck reaction was first reported by Mizoroki and Heck in 1968 and it has 
proved to be an important coupling reaction between terminal alkenes and aryl and vinyl 
halides.62 The Heck reaction is widely used in constructing complex natural products.63 We 
decided to examine the use of a Heck reaction in the preparation of compound 2.17 through 
the reaction with aryl halide 2.3 and our previously synthesised Baylis-Hillman adduct 
2.18. 
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Scheme 2.7: Proposed Heck reaction of 2.3 and 2.18 to give 2.17. 
We therefore examined the synthesis of 2.17 through the coupling of 2-bromo-1,4-
dimethoxybenzene 2.3 with 2.18, catalysed by palladium diacetate in the presence of 
triphenylphosphine and triethylamine (TEA). After 21 hours at 100 °C, the 1H NMR and 
TLC of the reaction mixture showed the presence of a complex mixture of products. The 
desired product 2.17 appeared to be present in one of the fractions from column 
chromatography, however 2.17 was isolated along with several other compounds of similar 
Rf values. Analysis of this fraction by mass spectrometry showed the presence of the correct 
mass for 2.17, confirming its presence (Figure 2.2). 
 
Figure 2.2: Mass spectrum of column fraction containing 2.17. Top: Theoretical mass isotope pattern 
for 2.17. Bottom: Experimental spectrum. 
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 To understand why these coupling reactions did not succeed, we need to provide a 
brief overview of the Heck reaction concepts and mechanism. The Heck reaction is a 
coupling between an electrophilic aryl or vinyl halide (R-X, X= Br or I) and a nucleophilic 
alkene. The initial step the Heck reaction is the generation of an electron rich palladium (0) 
which can then readily undergo an oxidative addition into arylhalide or vinylhalide bond to 
give a RPdXL2 species. The alkene then coordinates to the RPdXL2 species followed by 
migratory insertion to form a σ bond complex with the palladium. Then hydride 
elimination occurs to produce the desired trans-substituted alkene product. The final step 
in the Heck catalytic cycle is then the reductive elimination of HX from the HPdXL2 
intermediate and regenerating the catalyst L2Pd (Scheme 2.8).
64,65,66 
 
Scheme 2.8: Heck Reaction Mechanism. 
 Therefore, to improve the outcome of our Heck reaction we decided to examine 
methods that could speed up the oxidative insertion step to 2-bromo-1,4-dimethoxybenzene 
2.3. Thus we wished to investigate the use of σ-donating trialkylphosphine ligands in place 
of triphenylphosphine to increase the electron density on the palladium and thus facilitate 
the oxidative addition step. 
 
2.4.4. Attempt to Optimise Heck Reaction Condition  
 G. Fu and M. Netherton developed a new approach for the coupling of arylbromides 
and alkenes by employing a trialkylphosphine ligand as an alternative to 
triphenylphosphine to enhance the rate of the Heck reaction. Because trialkylphosphines 
are air sensitive, they were converted into their conjugate acids to form the corresponding 
air-stable phosphonium salts. In the case of Heck reaction, trialkylphosphonium salt [(t-
Bu)3PH]BF4 was used as an in situ source of (t-Bu)3P in the presence of a weak base.
67 We 
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therefore attempted the Heck coupling reaction of 2-bromo-1,4-dimethoxybenzene 2.3 and 
alkene 2.18 using tris(dibenzylideneacetone)dipalladium(0), tri-tert-butylphosphine 
tetrafluoroborate and N,N-dicyclohexylmethylamine based on Fu and Netherton procedure. 
However after 12 hours of refluxing in dioxane no product could be detected in the 1H 
NMR of the crude product.  
 
 
Scheme 2.9: Attempted Heck reaction under Fu conditions 
 Although low yields of 2.17 could be observed under our first set of conditions, no 
improvement was obtained by employing σ-donating trialkylphosphine ligands. Next, we 
decided to optimise the Heck reaction conditions by employing a more reactive arylhalide. 
In order to find the optimum reaction conditions for the formation of 2.17, we therefore 
decided to examine the Heck coupling reaction between 2-iodo-1,4-dimethoxybenzene 
2.28 and Baylis-Hillman adduct 2.18.  
 
2.4.5. Examination of the Iodination of 1,4-Dimethoxybenzene 2.29  
 Therefore, the first step was to examine synthetic routes to aryliodide 2.28. We 
aimed to synthesise aryliodide 2.28 by an electrophilic aromatic substitution reaction of 
1,4-dimethoxybenzene 2.29 with an electrophilic source of iodine (Scheme 2.10).  
 
Scheme 2.10: Proposed route to 2-iodo-1,4-dimethoxybenzene 2.28. 
 M. C. Carreño reported a method for iodinating methoxybenzenes and naphthalenes 
using N-iodosuccinimide (NIS) as a source of iodine in acetonitrile (Scheme 2.11).68 
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Scheme 2.11: Attempted iodination of 2.29 using NIS in acetonitrile. 
 Therefore, we investigated the reaction between 1,4-dimethoxybenzene 2.29 and 
NIS in acetonitrile. However after 22 hours at room temperature no product was observed. 
Repeating the reaction at reflux in the dark also failed to provide any of the desired product, 
with unreacted 2.29 still present. 
 Due to the poor results in the previous reaction we examined another approach for 
iodinating 1,4-dimethoxybenzene using iodine monobromide (IBr) as a source of I+. IBr 
can be generated in situ from NCS and NaI based on the work of Yamamoto.69 Using a 
modified method we reacted 1,4-dimethoxybenzene with NBS and NaI in AcOH at room 
temperature however after 20 hours. The 1H NMR of the resulting crude showed only the 
presence of the starting material 2.29 and the desired product 2.28 was not formed. 
 
Scheme 2.12: Attempted iodination of 2.29 using NBS and NaI. 
 Next we turned our attention to the iodination of 2.29 using the molecular iodine I2 
in DMSO based on a literature procedure.70 After 21 hours the reaction was quenched using 
sodium thiosulphate (Na2S2O3), however no product could be observed by 
1H NMR with 
only starting material 2.29 present. 
 
Scheme 2.13: Attempted iodination of 2.29 using I2 in DMSO. 
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 We continued our research to find an optimum condition for the synthesis of 2.28. 
N. Karade and his co-workers have developed an interesting procedure based on using a 
solvent-free method for halogenating arene substrates using NaCl, NaBr or I2 in the 
presence of hypervalent iodine (diacetoxyiodo)benzene (DIB) as an oxidising agent.71 We 
therefore examined the reaction between 1,4-dimethoxybenzene 2.29, iodine and DIB in 
acetonitrile at room temperature under an inert atmosphere. After 20 hours, the reaction 
was quenched with Na2S2O3. Gratifyingly, the 
1H NMR of the crude reaction mixture 
showed the appearance of the three promising peaks in the aromatic region at 7.35 ppm (d, 
J = 3.0 Hz, 1H), 6.87 ppm (dd, J = 9.1, 3.0 Hz, 1H) and 6.76 ppm (d, J = 9.1 Hz, 1H). This 
1H NMR pattern was indicative of a 1,2,4-substitution pattern in which the two methoxy 
groups are now inequivalent giving good evidence for a successful reaction. The desired 
product 2.28 was then isolated by column chromatography in a high yield of 78% (Scheme 
2.14 and Table 2.2). 
 
Scheme 2.14: Iodination of 2.29 using DIB and I2. 
 
No. Reaction Condition  %Yield 
1 NIS, MeCN Starting material 
recovered 2 NBS, NaI, AcOH 
3 I2, DMSO 
4 I2, DIB, MeCN, darkness, r.t., 20 hr  78 
Table 2.2: Examined reaction conditions towards 2.28. 
 After a successful formation of 2-iodo-1,4-dimethoxybenzene 2.28, we moved on 
exploring the Heck coupling reaction using 2.28. 
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2.4.6. Heck Coupling of Baylis-Hillman Adduct 2.9 and 2.28 
Next, we have examined the Heck coupling reaction of 2-iodo-1,4-
dimethoxybenzene 2.28 substrate with the terminal alkene in Baylis-Hillman adduct 2.18 
under the previous reaction condition. The coupling of 2.28 and 2.18 was catalysed by 
palladium diacetate in the presence of triphenylphosphine and TEA in DMF, the reaction 
was refluxed for 18 hours. However, the 1H NMR of resulting crude product include a 
complex mixture of compounds and we could not isolate the desired product 2.10 by 
column chromatography. 
 
Scheme 2.15: Heck coupling of 2.18 with 2-iodo-1,4-dimethoxybenzene 2.28. 
 Overall, these results indicated that the coupling of 1,4-dimethoxyaryl halide with 
the terminal alkene in Baylis-Hillman adduct 2.18 through a Heck reaction is difficult. It is 
most likely that the diethyl malonate substituents would lead to steric crowding at the 
alkene terminus and disrupt the coordination of the alkene to palladium metal. 
 
2.5. Synthesis of Ring A and B: Alternative Route for the Synthesis of 2.17 
 Since our planned route to molecule 2.17 involving a Heck reaction had not been 
successful, we decided to examine an alternative route to avoid the difficult Heck reaction 
step. Our new route involved the synthesis of unsaturated ketone 2.30 via a Wittig 
reaction of ylide 2.31 and the commercially available 2,5-dimethoxybenzaldehyde 2.32. 
Next, the desired compound 2.17 would be prepared through a Baylis-Hillman reaction of 
2.30 with diethyl ketomalonate 2.20 (Scheme 2.16).  
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Scheme 2.16: Proposed plan for the synthesis of 2.17. 
 
2.5.1. Synthesis of Ylide 2.31 and Unsaturated Ketone 2.30 
 The initial step in this plan involved in the synthesis of the Wittig reagent 1-
(triphenylphosphoranylidene)propan-2-one 2.31. First, Wittig salt 2.33 was prepared by an 
SN2 reaction of α-chloroacetone 2.34 and triphenylphosphine 2.35 in toluene under reflux. 
After 24 hours the phosphonium salt was isolated by filtration in a good yield of 78%. The 
phosphonium salt 2.33 was dissolved in DCM and then deprotonated with aqueous sodium 
hydroxide under phase transfer conditions to give 2.31. Recrystallization of 2.31 from 
toluene gave an isolated yield of 61%. Wittig reagent 2.31 was then reacted with 2,5-
dimethoxybenzaldehyde 2.32 in refluxing DCM for 48 hours and gave unsaturated 
ketone 2.30 as E-stereoisomer in a good yield 70% (Scheme 2.17).  
 
Scheme 2.17: Synthesis of 2.31 and 2.30. 
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 The stereochemistry of the alkene 2.30 was confirmed by the 1H NMR analysis, the 
alkene protons showing a coupling constant of J = 16.5 Hz, consistent with an E-alkene. 
The stereochemistry of 2.30 further confirmed by X-ray crystallography (Figure 2.3). 
Crystals of 2.30 were obtained by slow evaporation from a mixture of petroleum ether and 
diethyl ether (7:3). 
 
Figure 2.3: Single Crystal X-ray structure of 2.30. 
 
2.5.2. Synthesis of the Key Synthetic Intermediate 2.10 via Baylis-Hillman Approach  
 Next, we decided to investigate the use of a Baylis-Hillman reaction to functionalise 
the position of the substituted alkene 2.30 using the diethyl ketomalonate 2.20 in the 
presence of 10% of DABCO catalyst.  
  
Scheme 2.18: Attempt to produce 2.10 via a B-H reaction. 
 We therefore reacted 2.30 with diethyl ketomalonate 2.20 in the presence of 
DABCO. After 7 days at room temperature the 1H NMR of the crude product showed no 
reaction had occurred and the starting materials were still present. Increasing the reaction 
temperature to reflux for 2 days also did not show the production of any product (Table 
2.3). 
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No. Temperature  Time %Yield 
1 r.t. 7 days Starting material 
recovered 2 66 °C 2 days 
Table 2.3: Examination of a B-H reaction conditions towards 2.17. 
 
 This attempted Baylis-Hillman reaction has proven to be challenging. A number of 
studies indicate that a limitation of the Baylis-Hillman reaction is that it works best with 
terminal alkenes. The Baylis-Hillman reaction of substituted alkene often requires harsh 
reaction conditions such as high pressure.58 
 
2.6. Synthesis of Ring A and B: Synthesis of 2.17 via a Friedel–Crafts Reaction 
 Since the Baylis-Hillman reaction in the previous plan had proved to be 
unsuccessful, we postulated that compound 2.17 could be produced via a Friedel-Crafts 
reaction. The newly proposed synthetic route includes the generation of C=C bond in 2.17 
via an oxidation reaction of 2.36. Compound 3.36 could in turn be formed through the 
Friedel-Crafts reaction of 1,4-dimethoxybenzene 2.29 and the Baylis-Hillman adduct 2.18 
(Scheme 2.19). 
 
 
Scheme 2.19: Proposed route for the synthesis of 2.17 via a Friedel-Crafts reaction. 
 We therefore examined the proposed route to produce 2.17 intermediate through a 
Friedel–Crafts reaction. We carried out a F-C reaction between Baylis-Hillman adduct 2.18 
and 1,4-dimethoxybenzene 2.29 in the presence of different Lewis acids. We screened a 
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range of Lewis acids (TiCl4, BF3.O(C2H5)2 , DMAC), temperatures and solvents. The crude 
1H NMR of all reactions that involved the use of boron trifluoride diethyl etherate 
"BF3.O(C2H5)2" and dimethylaluminum chloride (DMAC) showed the presence of the 
starting material only. In the case of using titanium tetrachloride (TiCl4), peaks 
corresponding the terminal alkene of 2.18 were present along with several new peaks 
suggesting a number of molecules present which contain as ethyl ester group. Attempts to 
purify the desired product 2.36 from these complex mixtures proved unsuccessful. Due to 
the time constraint no further optimization reactions were possible (Table 2.4). 
 
Table 2.4: Examination of Friedel–Crafts reaction conditions towards 2.36. 
  
No. Lewis acid Solvent Temperature °C 
Time 
Product 
1 TiCl4 DCM -78 for 20 min, 
r.t. for 30 min 
 
C
o
m
p
le
x
 m
ix
tu
re
 o
f 
b
y
-
p
ro
d
u
ct
s 
 
2 TiCl4 DCM -78 for 3 hr,  
r.t. for 1 hr 
3 TiCl4 THF -78 for 30 min,  
r.t. for 15 hr 
4 BF3.O(C2H5)2 DCM -78 for 3 hr, 
r.t. for 15 hr 
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5 DMAC DCM 
6 BF3.O(C2H5)2 THF -78 for 30 min, 
r.t. for 15 hr 
 
7 DMAC THF 
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2.7. Conclusion 
 In conclusion, this chapter has examined three alternative synthetic routes towards 
the synthesis of 2.17 a key intermediate on the synthetic routes to our target natural product 
antibiotic DEM30355/A 1.14. In the first synthetic route to form 2.17 after a successful 
synthesis of Baylis-Hillman adduct 2.18, we examined Heck coupling of this Baylis-
Hillman adduct 2.18 and 2-bromo-1,4-dimethoxybenzene 2.3, which proved low yielding. 
Alongside the screening of alternative ligands for this reaction, we also attempted to 
optimise the Heck reaction through the use of 2-iodo-1,4-dimethoxybenzene 2.29 as a more 
reactive alternative coupling partner. However this reaction still did not give a significant 
yield of the desired product 2.17 to allow progress in the synthesis. Therefore, we 
developed a second route to produce 2.17 through a Baylis-Hillman reaction between our 
synthesised -substituted-,-unsaturated ketone 2.30 and diethyl ketomalonate 2.20. 
Unfortunately no reaction was observed, potentially due to the low reactivity of -
substituted-,-unsaturated ketones in Baylis-Hillman reactions despite the reactivity of 
the electrophile. In our final synthetic plan of this chapter we examined the production of 
2.36 via a Friedel–Crafts reaction  of 1,4-dimethoxybenzene 2.29 and Baylis-Hillman 
adduct 2.18 Although some promising results we obtained due to time constraints we did 
not pursue this reaction any further, the next chapter will look at an alternative approach to 
this synthesis. 
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Chapter 3 
3. Examination of Synthetic Routes to 1,2,3,4-substituted Aromatics Rings as 
Precursors in the Total Synthesis of DEM30355/A 1.14  
3.1. Introduction 
 The ring A of our target natural product antibiotic DEM30355/A 1.14 is a 1,2,3,4-
substituted aromatic ring, based on a hydroquinone structure. Therefore in this chapter we 
will examine synthetic routes to make the unusual 1,2,3,4-substitution pattern required. 
 If we consider a classical electrophilic aromatic substitution of a hydroquinone 
containing either an electron-donating or an electron-withdrawing group, the ortho-
directing effect of the electron donating group produces a product with a 1,2,4,5-
substitution pattern. Whereas the meta-directing effect of the electron withdrawing group 
gives a product with a 1,2,3,5-substitution pattern (Figure 3.1). 
 
Figure 3.1: Likely outcome of a classical electrophilic aromatic substitution of substituted 
hydroquinones (Coloured arrows show the directing effects of the different groups, Dashed arrows 
indicate sterically hindered positions). 
Therefore, classical methods cannot generate the 1,2,3,4-substituion pattern that we 
require for the synthesis of DEM30355/A 1.14, thus we will explore a number of unusual 
synthetic approaches towards our target molecules. 
 
3.1.1. Classic Methods for The Formation of 1,2,3,4-Substitued Aromatics 
3.1.1.1. Intramolecular Electrophilic Aromatic Substitution 
 Friedel–Crafts acylation reaction can be employed to generate hydroquinones with 
a 1,2,3,4-aromatic substitution pattern. The Friedel–Crafts acylation reaction of the 
hydroquinone 3.1 and succinyl dichloride 3.2 provides compound 3.3 with desired 
substitution pattern, as the second F-C acylation is intramolecular and thus is under steric 
control (Scheme 3.1).72 
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Scheme 3.1: Synthesis of the hydroquinone 3.3 via a F-C acylation. 
 
3.1.1.2. Diels-Alder Cycloaddition Reaction 
 Diels-Alder cycloaddition reaction (D-A) can also be used to generate 
hydroquinones with 1,2,3,4-aromatic substitution pattern. For example the cycloaddition 
reaction between the benzyne, formed by the deprotonation of 2-bromo-1,4-
dimethoxybenzene 2.3 with lithium diisopropylamide (LDA), and furan 3.4 to give product 
3.5 (Scheme 3.2).73 
 
Scheme 3.2: Synthesis of the hydroquinone 3.5 with via a D-A cycloaddition reaction. 
 The reaction mechanism involves in generating a benzyne intermediate 3.6 by 
removing a proton ortho to the bromine. The resulting benzyne 3.6 then can then undergo 
a cycloaddition reaction with furan 3.4 to form 3.5 (Scheme 3.3).73,74  
 
Scheme 3.3: Proposed mechanism for the synthesis of 3.5 with via a D-A cycloaddition reaction. 
 
 However both of these reactions have limitations, namely that they both give 
predominately symmetrical products and they require either strong Lewis acids or strong 
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Brønsted bases to generated the required reactive benzyne intermediate. An alternative 
approach to the 1,2,3,4-subsitution pattern could be the use of an ortho-lithiation chemistry. 
 
3.1.2. Directed Ortho-Lithiation Approach 
 Directed ortho-lithiation is a deprotonation on a site ortho to a directing group by 
an alkyllithium base, the subsequent addition of an electrophile gives a 1,2-disubstituted 
product. These directing groups contain a heteroatom that can coordinate to the lithium 
species directing the deprotonation. Examples include fluorine, amide and methoxy groups. 
Directed ortho-lithiation allows substitution at a sterically unfavourable position, thus we 
decided to examine this strategy in our synthesis (Scheme 3.4).75  
 
Scheme 3.4: Directed ortho-lithiation reaction of an aromatic ring. 
 
3.2. Synthesis of Ring A of DEM30355/A 1.14 via an Ortho-Lithiation Approach 
3.2.1. Planned Route for the Synthesis of Ring A via a Key Ortho-Lithiation Step  
 Based on this approach we devised a new synthetic plan, focused on 
building synthetic intermediate 2.16 that includes an aromatic ring with a 1,2,3,4-
substitution pattern. We envisioned that the ester moiety in compound 2.16 would be 
obtained from the acid chloride 3.7. The partially saturated six membered ring B in 
compound 3.7 could be formed via an intramolecular Baylis-Hillman reaction between the 
enolate and the ketone in 3.8. The formation of unsaturated ketone 3.8 could be 
achieved through Wittig reaction of 3.9. The ketone and the aldehyde in 3.9 would be 
obtained by removing acetals protecting groups in 3.10. Trapping the organolithium 3.11 
with electrophile 3.13 would produce 3.10. The organolithium 3.11 could be generated by 
ortho-lithiation reaction of 3.12 with n-butyllithium. The acetal 3.12 could be produced 
from the commercially available 2,5-dimethoxybenzaldehyde 2.32. Acid chloride 3.13 
could be prepared from ketomalonic acid 3.14 and thionyl chloride, followed by acetal 
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protection. Ketomalonic acid 3.14 could be produced from the hydrolysis of 2.20 (Scheme 
3.5).  
Scheme 3.5: New proposed synthetic route toward DEM30355/A 1.14 via a key ortho-lithiation 
reaction. 
 
3.2.2. Protection of 1,4-Dimethyoxybenzaldehyde 2.32 
 The first step in this plan involves protecting aldehyde 2.32 as a cyclic acetal to 
prevent the unwanted nucleophilic addition of n-BuLi to the aldehyde during our planned 
ortho-lithiation step. We have examined the formation of acetal 3.12 through the reaction 
of 2,5-dimethoxybenzaldehdye 2.32 with 10 equivalents of ethylene glycol in the presence 
of catalytic amount of acid, p-toluenesulfonic acid (p-TSA). After 2 hours the crude 
reaction mixture was purified by column to give 31% of the target product 3.12 and 63% 
of starting material was recovered. As the acetal formation is reversible, therefore we 
proposed that using both an excess of ethylene glycol and a Dean-Stark apparatus to remove 
the water formed would push the equilibrium in favour of the desired product 3.12. 
Following a number of optimisation attempts (Table 3.1), the best results were achieved 
after refluxing the reaction for 4 hours in a Dean-Stark apparatus, the resulting crude 
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material was purified by column chromatography to give the desired product 3.12 in a good 
yield 86%. 
 
No. Ethylene glycol equivalents Time (hr) %Yield 
1 10 2 31 
2 30 2 61 
3 30 4 86 
Table 3.1: Examined reaction conditions for protecting aldehyde 2.32 as a cyclic acetal. 
 
3.2.3. Ortho-Deprotonation Reaction of 3.12 
 As the first step in the investigation of our planned ortho-lithiation, we decided to 
test the ortho-litihation reaction by trapping 3.12 with D2O to allow us to easily optimise 
the deprotonation step. Therefore, we examined the ortho-litihation approach through the 
reaction of the acetal 3.12 with n-BuLi at 0 °C. After 3 hours, the reaction was quenched 
with deuterated water (D2O) to confirm the deprotonation site on the aromatic ring. 
 
Scheme 3.6: Examination of the deprotonation of 3.12. 
 Despite attempting the deprotonation for different lengths of time (0 oC for up to 3 
hours) we did not observe the formation of the product 3.15 in the 1H NMR of the crude 
product, where we have anticipated that the peak at δH 7.12 ppm would decrease in intensity 
if deuteration had been successful. It has been reported that this type of deprotonation at 
such a hindered site ortho- to the acetal can require up to 10 hours to occur at low 
temperature.76 Due to the poor results for this reaction we decided to focus on alternative 
approaches. Simultaneous to this work we also investigated an alternative bromination 
approach to generate the desired substitution pattern discussed below. 
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3.3. Synthesis of Ring A of DEM30355/A 1.14 via Thiele-Winter Like Bromination 
Approach 
3.3.1. Planned Route for the Synthesis of Ring A via a Key Bromination Step  
 We have thus considered another approach for functionalising position 3 of the ring 
A of DEM30355/A 1.14 based on Thiele-Winter like bromination of the commercially 
available 2,5-dihydroxybenzaldehyde 3.21. The retrosynthesis of the synthetic intermediate 
2.16 involved in an intramolecular Baylis-Hillman reaction followed by the esterification 
of 3.7. Next, unsaturated ketone 3.7 would be regenerated by removing the acetal 
protecting groups from 3.16. Halogen-metal exchange reaction of 3.17 trapped with 3.13 
would produce 3.16. For a successful halogen-metal exchange reaction, the carbonyl of 
unsaturated ketone 3.18 should be converted to acetal 3.17. Wittig olefination of 
aldehyde 3.19 would generate -unsaturated ketone 3.18. Compound 3.19 could be 
produced through the methylation reaction of 3.20. The desired 1,2,3,4-aromatic 
substitution pattern could be achieved through a regioselective Thiele-Winter like 
bromination of the commercially available aldehyde 3.21 to give 3.20 (Scheme 3.7). 
 
Scheme 3.7: Proposed synthetic route toward DEM30355/A 1.14 via a key bromination reaction. 
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3.3.2. Thiele-Winter Reaction 
The reaction of p-benzoquinone with acetic anhydride in the presence of a catalytic 
amount of sulfuric acid to yield 1,2,4-triacetoxybenzene was studied by J. Thiele in 1898. 
Further investigation was carried out by Thiele and his student E. Winter to study the 
reaction of other quinones such 1,2-benzoquinone and naphthoquinones with acetic 
anhydride catalysed by ZnCl2 . They found that the acid catalysed reactions of quinones 
with acetic anhydride give triacetoxy aromatic compounds (Scheme 3.8).77 
 
Scheme 3.8: First reaction reported by J. Thiele. 
 The mechanism of Thiele-Winter acetoxylation reaction involves 1,4-addition of 
the acetate ion to an activated quinone to generate the corresponding mono-acetoxy 
hydroquinone, the resulting hydroquinone then further reacts with acetic anhydride to give 
1,2,4-triacetoxybenzene (Scheme 3.9) 
Scheme 3.9: Thiele-Winter acetoxylation reaction mechanism. 
 
 In 1999, C. Correia and W. Almeida reported that the total synthesis of 
metachromin A 3.24 was achieved by Thiele-Winter acetoxylation as a key step reaction. 
Thiele-Winter reaction involved in the regioselective 1,4-addition of acetic anhydride to 
quinone 3.25 in the presence of sulfuric acid gave compound 3.26 that matches our desired 
aromatic substitution pattern.(Scheme 3.10).78  
Chapter 3 Examination of Synthetic Routes to 1,2,3,4-Substituted Aromatics 
Rings as Precursors in the Total Synthesis of DEM30355/A 1.14  
 
 
47 
 
 
Scheme 3.10: The total synthesis of metachromin A 3.24 mediated by Thiele-Winter reaction. 
 
3.3.3. Porco Bromination 
 J. Porco et al. reported unusual bromination reaction of 2,5-dihydroxybenzaldehyde 
3.20 to generate hydroquinone compound 3.19 with 1,2,3,4-aromatic substitution pattern 
(Scheme 3.11).79 
 
Scheme 3.11: Bromination of 3.21 reported by Porco. 
 We proposed that the mechanism of the bromination of 2,5-dihydroxybenzaldehyde 
3.21 reaction includes the oxidation of hydroquinone 3.21 into a p-benzoqunione type 
compound. Similar to Thiele-Winter acetoxylation reaction, the next step involved in 1,4-
addition of the bromine anion to the α,β-unsaturated ketone (Scheme 3.12).  
 
Scheme 3.12: Proposed mechanism for the synthesis of 3.20.  
 
 Subsequently, as 2-bromo-3,6-dihydroxybenzaldehyde 3.20 represents a 
hydroquinone with 1,2,3,4- aromatic substitution pattern, it has been widely used as a 
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building block for the total synthesis of many natural products and bioactive compounds 
including (-)-kinamycin C180 3.27, (−)-jesterone81 3.28, torreyanic acid79 3.29 and (+)-
clavilactone A82 3.30, and it could also be utilized as a building block for the synthesis of 
DEM30355/A 1.14 (Scheme 3.13). 
 
Scheme 3.13: The total synthesis of many natural products using 3.20 as a starting material. 
 Therefore, we planned to investigate the synthesis of DEM30355/A 1.14 using 2-
bromo-3,6-dihydroxybenzaldehyde 3.20 as a key building block. 
 
3.3.4.  Synthesis of 2-Bromo-3,6-dihydroxybenzaldehyde 3.20 
 Based on the Porco procedure, we examined the synthesis of 3.20 through the 
regioselective bromination of 2,5-dihydroxybenzaldehyde 3.21.79 We started our reaction 
by a dropwise addition of molecular bromine to 3.21 in chloroform over 30 minutes. After 
1.5 hours the reaction was quenched and washed several times with Na2S2O3, extracted 
organic layer was dried over MgSO4. The resulting crude reaction mixture was purified by 
column to give product 3.20 in 93%. In the second attempt we examined the effect of 
changing the drying agent from MgSO4 to Na2SO4 since in the first attempt MgSO4 
remained yellow even after using a large amount of wash solvent, potentially due to the 
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chelation between magnesium and the oxygens of 3.20. We found that increasing the 
reaction time to 2.5 hours after bromine addition, along with drying the organic layer over 
Na2SO4 enhanced the yield of the desired product 3.20 to be 99% (Table 3.2).  
 
No. Drying agent Time (hr) %Yield 
1 MgSO4  1.5 93 
2 Na2SO4 2.5 99 
Table 3.2: Examination on the bromination reaction of 3.21. 
 
 In the first attempt the dimer 3.31 was isolated as a minor component in a low yield 
5% (Figure 3.2). 
 
Figure 3.2: The structure of dimer 3.31. 
 
 Crystals of dimer 3.31 were obtained by slow evaporation from a mixture of 
petroleum ether and diethyl ether (1:1). The crystal structure of 3.31 was obtained through 
single crystal X-ray crystallography (Figure 3.3). 
 
Figure 3.3: Crystal structure of the dimer 3.31. 
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 Comparing to ortho-lithiation approach, the formation of desired substitution 
pattern was achieved via bromination approach to give 3.20 in an excellent yield 99% in 
shorter reaction time. Moreover, the deprotonation reaction required strictly anhydrous 
conditions whereas the bromination reaction is water tolerant. Furthermore ortho-lithiation 
reactions are difficult to perform on a large scale, due to the low temperatures and the 
reactivity of BuLi, whereas the bromination approach is easier to perform in the lab, as 
exemplified in the total synthesis of (+)-torreyanic acid 3.29.79  
 
3.3.5. Methylation of 2-Bromo-3,6-dihydroxybenzaldehyde 3.19 
 After a successful formation of 3.20, we turned our attention to produceing 3.19 via 
a double methylation reaction of 3.20. The problem in the di-methylation of 3.20 is that the 
two phenolic oxygens do not have the same reactivity. We expected that the phenolic 
oxygen ortho to the aldehyde are less reactive than the other phenolic oxygen due the 
hydrogen bonding (Figure 3.4). 
 
Figure 3.4: The hydrogen bonding between the aldehyde and adjacent phenolic OH in 3.20. 
 
Thus, we found that the aldehyde protection could be a reasonable solution to 
disrupt the effect of hydrogen bonding between the aldehyde and hydroxyl. 
 
3.3.5.1. Aldehyde Protection of 2-Bromo-3,6-dihydroxybenzaldehyde 3.20 
 Therefore, we examined converting aldehyde 3.20 into a corresponding acetal 3.32 
through the reaction of 3.20 with ethylene glycol catalysed by p-TSA in a Dean-Stark 
apparatus. After refluxing the reaction for 4 hours, the 1H NMR of the crude material 
indicated that the reaction did not move to completion (estimated conversion 31%). The 
conversion could be low because the hydrogen bonding between the aldehyde and the 
phenolic hydroxyl is strong. 
Chapter 3 Examination of Synthetic Routes to 1,2,3,4-Substituted Aromatics 
Rings as Precursors in the Total Synthesis of DEM30355/A 1.14  
 
 
51 
 
 
Scheme 3.14: Acetal protection of 3.20. 
 Due to the low yielding product 3.32 obtained from the acetal protection, we moved 
to an alternative solution that depends on protecting the most reactive phenolic oxygen. 
 
3.3.5.2. Regioselective Protection of Phenolic Hydroxyl 3.20 
 Alternatively, we planned to protect the reactive phenol through the regioselective 
silylation reaction. Next the methylation of the less reactive phenol will be examined. Based 
on a literature procedure, we examined the protection of the phenolic oxygen using the 
silylation agent tert-butyldimethylsilylchloride (TBDMSCl) and imidazole in DCM.79 The 
synthesis of 3.33 was successfully achieved after a column purification, however, the 
isolated yield of 3.33 was relatively low 41%. At the next step, we examined the 
methylation of protected phenol 3.34 using methyl iodide and potassium carbonate in THF. 
After refluxing the reaction for 24 hours, the mono-methylated product 3.34 was isolated 
by column in a moderate yield 58%. 
 
Scheme 3.15: The synthesis of 3.33 and 3.34. 
 Although the methylation of the more unreactive phenolic oxygen was achieved, 
the formation of the di-methylated compound 3.19 required silyl deprotection and 
additional methylation step. The expected overall yield of the di-methylated product 3.19 
will be low. Therefore we alternatively decided to methylate both phenolic positions in 3.20 
in a single step. A few number of studies demonstrated that the double methylation of 
hydroquinones and other related phenols can be accomplished under vigorous conditions 
by refluxing toxic dimethyl sulfate and potassium hydroxide or potassium carbonate for at 
least 24 hours.83,84 In particular, the double methylation of 2-bromo-3,6-
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dihydroxybenzaldehyde 3.20 was only reported by Takao and his co-worker using Me2SO4 
and K2CO3 in DMF to provide compound 3.19 in a moderate yield.
82 
 
Scheme 3.16: Methylation of 3.20 using dimethyl sulfate. 
 However, we have not employed dimethyl sulfate as a methylating agent because it 
is extremely toxic. In the following section we have discussed several conditions that we 
examined for methylating the two phenolic OH groups of 2,5-dihydroxybenzaldehyde 3.20 
in a single step using different methylating agents and various bases. 
 
3.3.5.3. Direct Double O-Methylation of 3.20  
 We have explored the synthesis of di-methylated product 3.19 through the 
methylation of 2-bromo-3,6-dihydroxybenzaldehyde 3.20 by screening various 
methylating agents, bases, solvents and temperature. We considered using 
trimethyloxonium tetrafluoroborate (Meerwein’s salt) along with methyl iodide as 
methylating agents. Meerwein’s salts are alkylating agents that refer to any complex 
consists of trialkyloxonium with a strong Lewis acid, they discovered by Hans Meerwein 
in 1937. 85 (Table 3.3). 
 
No. Methyl 
-ating agents 
Base Solvent Temp 
°C 
Time 
hr 
Product % 
1 Me3O(BF4) Hünig’s DCM 0 then 
r.t. 
 
24 
 
 
 
Not observed 
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2 MeI NaH THF r.t. and 
66 
24  
 
 
 
 
 
 
 
 
 
Not observed 
 
3 MeI NaH DCM r.t .and 
40 
24 
 
4 MeI Hünig’s DCM r.t .and 
40 
18 
5 MeI K2CO3 acetone r.t and 
56 
24 
6 MeI K2CO3 DCM r.t and 
40 
24 
7 MeI K2CO3 DMSO r.t. 24 
8 MeI K2CO3 DMF r.t. 24 
 
9 Me3OBF4 Hünig’s 
 
DCM  0 to r.t. 36 
 
3.35 
45 
10 MeI NaOMe MeOH 
 
64 24 8 
11 MeI 
 
K2CO3 THF 40 24 
 
3.19 
 
30 
12 MeI 
 
K2CO3 THF: 
DMF 
10:1 
40 24 37 
13 MeI, 
 
K2CO3 
assisted by 
TBAB 
THF: 
DMF 
10:1 
40 24 75 
Table 3.3: Examined conditions towards the methylation of 3.20. 
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 We started our investigation towards producing 3.19 by using a trimethyloxonium 
tetrafluoroborate and Hünig’s base (i-Pr2NEt) in DCM at 0 °C. After 36 hours the mono 
methylated product 3.35 was isolated by column in a moderate yield 45%. We have 
examined the previous condition using methyl iodide as an alternative methylating agent. 
However, no product was obtained, the 1H NMR of crude reaction showed a complex 
mixture compounds and no product was observed. 
 Next, we decided to consider the use of methyl iodide as a methylating agent and 
we continued to screen for a perfect base and solvent system. We examined another 
condition that includes refluxing methyl iodide and sodium methoxide in methanol. After 
24 hours the mono-methylated product 3.35 was isolated by a column chromatography in 
a low yield 8%. 
 We continued our investigation to produce 3.19 by screening another condition 
using sodium hydride and methyl iodide in THF at different temperatures. However, the 1H 
NMR of crude reaction showed a complex mixture of by-products, and product 3.19 was 
not observed. Next, we have used DCM as an alternative solvent, unfortunately, product 
3.19 also was not seen.  
 Next, we continued our effort to find the optimum conditions for producing 3.19, 
we examined the use of potassium carbonate and methyl iodide by screening range of 
solvents including acetone, DCM, THF, DMF and DMSO. After extensive investigations, 
the formation of the dimethylated product 3.19 was successfully achieved by heating 
methyl iodide and potassium carbonate in THF at 40 °C for 24 hours. The desired product 
3.19 was isolated by column in a moderate yield 30%. To improve the yield of 3.19, the 
previous reaction was repeated using a mixture of solvents THF:DMF 10:1. It was found 
that the addition of freshly distilled DMF slightly increases the yield of product 3.19 to be 
37%. Interestingly, the yield of 3.19 was significantly improved to 75% by using the phase 
transfer catalyst tetrabutylammonium bromide (TBAB), potentially through an increase in 
the solubility of the inorganic base in the organic solvent. 
 After a successful formation of di-methylated compound 3.19, we turned our 
attention into constructing the upper part of our target molecule 1.14 that includes 
unsaturated ketone through the formation of 3.36. 
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3.3.6. Synthesis of (E)-4-(2-Bromo-3,6-dimethoxyphenyl)but-3-en-2-one 3.36 
We therefore planned to synthesize unsaturated ketone 3.36 by refluxing the 
methylated compound 3.19 with a previously prepared Wittig ylide 2.31 in THF. After 
60 hours, the desired product 3.36 was isolated by column in an excellent yield 94%. 
 
Scheme 3.17: The synthesis of 3.36. 
 With 3.36 in hand, we aim to protect the resulting ketone to prevent any unwanted 
side reactions in subsequent steps. 
 
3.3.7. Protection of (E)-4-(2-Bromo-3,6-dimethoxyphenyl)but-3-en-2-one 3.37 
 We therefore examined the acetal protection of ketone by refluxing 3.36 with 
ethylene glycol and p-TSA in toluene for 4 hours in a Dean-Stark apparatus. Purification 
of the crude reaction mixture by column chromatography gave product 3.37 in a low yield 
13% and most of the starting material was recovered. 
 
Scheme 3.18: Acetal protection of 3.36. 
 
 Due to the low yielding of 3.37, we considered an alternative method for protecting 
3.36, via a chemoselective reduction of the ketone using diisobutylaluminum hydride 
(DIBAL-H) as a reducing agent to produce the corresponding alcohol 3.38. Thus, we 
investigated the reaction of 3.36 with DIBAL-H in toluene at -78 °C for 30 min. Quenching 
the reaction with cold methanol followed by washing the reaction mixture with diluted HCl, 
lead accidentally to methylate the resulting alcohol and gave 3.39 instead of 3.38. The 
isolated yield of compound 3.39 is 38% yield. Therefore, we repeated the previous reaction 
under the same condition and we quenched the reaction with cold water only following by 
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aqueous work-up with NH4Cl. the resulting crude product was purified by column 
chromatography to give the desired alcohol 3.38 in a high yield 94%. 
 
Scheme 3.19: The synthesis of 3.38 and 3.39. 
 Due to time constraint the protection of alcohol 3.38 will be continued in the future. 
 
3.3.8. Biological Assay of the Synthetic Intermediates 2.30 and 3.36 
 As the mode of action of our antibacterial agent DEM30355/A 1.14 is unclear, we 
proposed that 1.14 could be a Michael acceptor as it contains unsaturated ketone in its 
structure. Due to the structural similarity between 1.14 and our synthetic intermediates 2.30 
and 3.36, we planned to explore the pharmacophore of 1.14 by investigating the biological 
activity of 2.30 and 3.36 against the Gram-positive bacterium, Bacillus subtilis (Figure 
3.5). 
 
Figure 3.5: Structures of DEM30355/A 1.14, 2.30 and 3.36. 
 
 However, 2.30 and 3.36 showed no activity against Bacillus subtilis strain. 
Therefore, based on this result we suggest that the DEM30355/A 1.14 is not a Michael 
acceptor and its potency might originate from a binding event with a key enzyme in the 
bacteria (Figure 3.6). 
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Figure 3.6: Bioassay of 2.30, 3.36 and DEM30355/A 1.14. Red circle highlights halo of inhibition. 
Bioassay performed by Dr B. Kepplinger. 
 
3.4. Conclusion 
 In this chapter two synthetic routes were examined towards the formation of ring A 
of 1.14 that includes hydroquinone with 1,2,3,4-substitution pattern. The first route based 
on the directed ortho-lithiation, whereas the second route includes the bromination of 2,5-
dihydroxybenzaldehyde 3.21 in a similar nature to Thiele-Winter acetoxylation reaction. 
Best result was obtained using a bromination approach as compound 2-bromo-3,6-
dihydroxybenzaldehyde 3.20 was formed in an excellent yield up to 99%. After 
considerable investigations we developed a new method for methylating 3.20 to produce 
3.19 which is identical to ring A in 1.14. After that, we have successfully built -
unsaturated ketone 3.36 that presents in ring B and C of 1.14 through the reaction of 3.19 
with the previously synthesised Wittig reagent 2.31. The keto group ofunsaturated 
ketone 3.36 was selectively reduced to give the corresponding alcohol 3.38 in a high yield. 
 
3.5. Future Work 
 The synthesis of rings A and B in 1.14 could be achieved through the protection of 
hydroxyl group in 3.18 with MOMCl followed by a halogen-metal exchange reaction using 
n-BuLi, trapping with 3.13 to give the synthetic intermediate 3.41. After removal of the 
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protecting groups we would attempt an intramolecular Baylis-Hillman reaction of 3.7 to 
give the core structure of DEM30355/A 1.14. 
 
 
Scheme 3.20: Towards the synthesis of rings A and B of DEM30355/A 1.14. 
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Chapter 4 
4. Studies towards the Total Synthesis of DEM30355/A 1.14 via an 
Intramolecular Aldol Condensation 
 This chapter describes our efforts towards the formation of DEM30355/A 1.14 
following a new strategy based on the synthesis of the aromatic ring A, then building the 
more complex rings C and D, followed by coupling the fragments via an intramolecular 
aldol condensation to construct ring B.  
 
4.1. Retrosynthetic Analysis of DEM30355/A 1.14 Based on an Intramolecular 
Aldol Condensation Approach 
 We envisioned that DEM30355/A 1.14 could be generated by the deprotection of 
compound 4.1. Unsaturated ketone 4.1 could be formed through an intramolecular 
aldol condensation between the aldehyde and ketone in compound 4.2 followed by 
oxidation of the tertiary carbon and lactone formation. Aldehyde 4.2 could be produced 
through the oxidation of the primary alcohol 4.3. Compound 4.3 would be obtained by a 
nucleophilic addition of an organometallic 4.4 to benzaldehyde 4.5 (Scheme 4.1).  
Scheme 4.1: Retrosynthesis of DEM30355/A 1.14 following intramolecular aldol condensation 
approach. 
 The organometallic compound 4.4 could be formed, via a hydroxyl to halogen 
conversion and oxidative insertion of a suitable metal, from 4.6. An intramolecular aldol 
cyclization between aldehyde and ketone in compound 4.7 could be employed to form 4.6. 
The hydrolysis of cyclic acetals and ester group in compound 4.8 would give 4.7, whilst 
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the nucleophilic addition of the anion 4.10 to the ketone 4.9 would provide the compound 
4.8 which is the carbon skeleton for the C and D (lactone) ring (Scheme 4.2).  
 
Scheme 4.2: Retrosynthesis of ring C and D. 
 We envisioned that alkene 4.9 could be formed by reducing the alkyne 4.11 under 
a hydrogen atmosphere. The ketone in compound 4.11 could be prepared through the 
oxidation of the secondary alcohol 4.12. The alkyne moiety in 4.12 could be obtained 
through a nucleophilic addition of a Grignard regent to aldehyde 4.13. The oxidation of the 
commercially available solketal ((2,2-dimethyl-1,3-dioxolan-4-yl)methanol) 4.14 would 
produce aldehyde 4.13 (Scheme 4.3). 
 
Scheme 4.3: Retrosynthesis of the synthetic intermediate 4.9. 
 
 Next, the synthetic intermediate 4.10 could be obtained through the protection of 
ketone 4.15. The secondary alcohol 4.16 could be also protected as a PMB ether to provide 
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compound 4.15. Aldol reaction between ethyl glyoxalate 4.17 and acetone 4.18 would 
generate hydroxy carbonyl 4.16 (Scheme 4.4). 
 
Scheme 4.4: Retrosynthesis of the synthetic intermediate 4.10. 
 
4.2. Synthesis of Ring C and D of DEM30355/A 1.14 an via an Intramolecular Aldol 
Condensation Approach 
4.2.1. Synthesis of 2,2-Dimethyl-1,3-dioxolane-4-carbaldehyde 4.13 
 (R)- and (S)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde 4.13 are useful and 
affordable chiral building blocks for constructing chiral centers in the total synthesis of 
many natural products such as prostaglandins,86 clavalanine87 4.19 and agglomerins 
antibiotics88 4.20 (Figure 4.1). 
 
Figure 4.1: Natural products formed from 2,2-dimethyl-1,3-dioxolane-4-carbaldehyde 4.13. 
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 We have investigated the formation of the synthetic intermediate 2,2-dimethyl-1,3-
dioxolane-4-carbaldehyde 4.13 through the oxidation of (2,2-dimethyl-1,3-dioxolan-4-
yl)methanol 4.14 by examining different approaches (Scheme 4.5). 
 
Scheme 4.5: Proposed reaction for the synthesis of 4.13. 
 
 J. Hong et al demonstrated that the oxidation of (2,2-dimethyl-1,3-dioxolan-4-
yl)methanol 4.14 with pyridinium chlorochromate (PCC) gave the corresponding 4.13.89 
based on the Hong procedure, we examined the oxidation of 4.14 with PCC at 0 °C for 6 
hours. However, no peak corresponding to the aldehyde was observed in the 1H NMR of 
the crude reaction, even after repeating the reaction at room temperature for different 
lengths of time (6 hours and 12 hours). 
 
Scheme 4.6: Attempted oxidation of 4.13 with PCC. 
 Next, we have examined the synthesis of 4.13 through a Swern oxidation of 4.14. 
Based on a literature procedure, we reacted DMSO with oxalyl chloride in DCM at -78 °C 
to generate the reactive chlorosulfonium intermediate.90 After 15 minutes chlorosulfonium 
intermediate was further reacted with 4.14 in the presence of triethylamine (TEA) base. 
The reaction crude was purified by column to give aldehyde 4.13 in a low yield 17%. 
 
 
Scheme 4.7: Oxidation of 4.14 via Swern reaction. 
 
 Due to the low yielding product obtained from Swern oxidation of 4.14, we have 
examined a third approach that involves in generating (R)-2,2-dimethyl-1,3-dioxolane-4-
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carbaldehyde (R)-4.13 through the oxidative cleavage of diol 4.21. Compound 4.21 could 
be prepared from D-mannitol 4.22 (Scheme 4.8). 
 
 
Scheme 4.8: Retrosynthesis of the (R)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde 4.13. 
 
 In the first step we examined the synthesis of 4.21 through the double acetal 
protection of D-mannitol 4.22 based on Tipson and Cohen method.91 We started our 
investigation by reacting D-mannitol 4.22 with ZnCl2 and acetone for 24 hours. Quenching 
the reaction with a saturated solution of K2CO3 produced the desired product 4.21 in 48% 
yield after recrystallisation from cyclohexane. 
 
Scheme 4.9: Synthesis of the 4.21. 
 With 4.21 in hand, we investigated the formation of compound (R)-4.13 by reacting 
4.21 with NaIO4 and NaHCO3 in DCM at room temperature based on a literature 
procedure.92 After 2 hours, the reaction was dried with Na2SO4 and filtered. The desired 
product (R)-4.13 was successfully purified by distillation in a high yield 99%. 
 
 
Scheme 4.10: Synthesis of (R)-4.13 from D-mannitol 4.22. 
 
 Overall, the synthesis of (R)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (R)-4.13 
was successfully achieved from D-mannitol 4.22 under mild conditions in a good yield in 
comparison to the PCC/Swern oxidation approaches (Table 4.1). 
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No. Starting material Reaction Condition Product  %Yield 
1 
 
4.14 
PCC 
0 °C for 6 hours 
Starting material was 
recovered 
0 
2 
 
4.14 
PCC 
r.t. for 6 hours 
Starting material and 
minor peak for by-
products, no product 
was observed 
0 
3 
 
4.14 
PCC 
r.t. for 12 hours 
Starting material and 
minor peak for by-
products, no product 
was observed - 
0 
5 
 
4.14 
(COCl)2, DMSO 
DCM, -78 °C for 15 
min then TEA 
r.t for 1 hour 
 
4.13 
17 
6 
 
4.21 
NaIO4, NaHCO3 
DCM 
r.t. for 2 hours 
 
 
(R)-4.13 
99 
Table 4.1: Examination of the synthesis of 2,2-dimethyl-1,3-dioxolane-4-carbaldehyde 4.13 under 
different conditions. 
 
4.2.2. Grignard Addition of 1-Propynylmagnesium Bromide to (R)-4.13 
 After a successful synthesis of (R)-4.13, we planned to construct the alkyne chain 
in compound 4.12 via the nucleophilic addition of the Grignard reagent into the aldehyde 
(R)-4.13. Based on a literature procedure, we examined the reaction of (R)-4.13 with 1-
propynylmagnesium bromide in THF.93 After 4 hours the 1H NMR of the crude reaction 
mixture showed the presence of a distinctive multiplet peak at 4.37 ppm corresponding to 
the proton at the C4’ position of 4.12. Purification by chromatography of the crude reaction 
mixture gave 4.12 in a moderate yield 28% as a mixture of two diastereoisomers. After 
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extending the reaction time for 12 hours, the yield of product 4.12 was improved to 63% 
(Table 4.2). 
 
No.  Reaction time (hr) %Yield  
1 4 28 
2 12 63 
Table 4.2: Examination of Grignard reaction of (R)-4.13 towards 4.12. 
 
4.2.3. Swern Oxidation of 4.12 
 Next, we turned our attention to the synthesis of 4.11 via a Swern oxidation of 4.12. 
We therefore reacted 4.12 under classical Swern conditions. The loss of the stereocenter at 
the C1 position could be confirmed as the 1H NMR of the desired product 4.11 was 
significantly simplified compared to the diastereomeric mixture observed with 4.12. 
However, the isolated yield of the product was low 15%. To improve the yield of 4.11 we 
repeated the Swern reaction but extended the reaction time after the addition of TEA to 90 
minutes. After aqueous work up the 1H NMR of the crude product showed a complete 
conversion of the starting material giving the product 4.11 in a quantitative yield with no 
further purification required (Table 4.3). 
 
No. Reaction time following the 
addition of TEA (min) 
%Yield 
1 15 15 
2 90 100 
Table 4.3: Examination of Swern oxidation of 4.12 towards 4.11. 
 Due to the time constraint the subsequent planned reduction of alkyne 4.11 into the 
corresponding (Z)-alkene 4.9 will be continued in the future.  
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4.2.4. Investigation of the Aldol Reaction of 4.18 and 4.17 
 Next, we turned our attention to exploreing the synthesis of 4.16 through an aldol 
reaction between ethyl glyoxalate 4.17 and acetone 4.18  
 
Scheme 4.11 Proposed reaction for the synthesis of 4.16. 
 We started our investigation by deprotonating acetone 4.18, with sodium methoxide 
in THF, to generate the corresponding enolate, afterward ethyl glyoxalate 4.17 was added 
to the reaction. After 6 hours none of the desired product was observed by 1H NMR of the 
reaction crude, with a complex mixture being formed. 
 
Scheme 4.12: Attempted reaction to produce 4.16 using NaOMe. 
 
 In the second attempt we have used a bulky base lithium diisopropylamide (LDA) 
to generate the acetone enolate in THF at -78 °C, to which was added ethyl glyoxalate 4.17. 
After 3 hours the desired product 4.16 was not observed in the 1H NMR of the crude 
reaction. 
 
Scheme 4.13: Attempted reaction to produce 4.16 using LDA. 
 
 Next, we examined another method that involved using pyrrolidine as an 
organocatalyst. The reaction of acetone 4.18 and ethyl glyoxalate 4.17 was performed in 
water at room temperature in the presence of a catalytic amount of pyrrolidine. After 3 
hours, the 1H NMR of the crude reaction mixture showed the presence of two new 
distinctive double doublet peaks at 2.98 (dd, J = 17.4, 4.1 Hz) and 2.89 (dd, J = 17.4, 6.2 
Hz) corresponding to methylene group of the desired product 4.16. However the 
purification of the crude reaction mixture by column chromatography gave the product 4.16 
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in a low yield 8%. We then attempted to optimise the reaction conditions by extending the 
length time of the reaction to 12 hours, which the yield of 4.16 increased to 14% (Table 
4.4). 
 
No. Reaction Condition %Yield  
1 1) 4.18, NaOMe, THF, 0°C for 30 minutes 
2) 4.17, r.t. 6 hr 
Complex mixture of 
by-product 
No product was 
observed 
2 1) 4.18, LDA, THF, -78 °C for 20 minutes 
2) 4.17, r.t. 3 hr 
Complex mixture of 
by-product 
No product was 
observed 
3 pyrrolidine, H2O 8 
4 pyrrolidine, H2O 14 
Table 4.4: Examination of aldol reaction between 4.17 and4.18 under different conditions. 
 The desired aldol reaction to give 4.16 has been successfully demonstrated, 
however further optimisation of the reaction will be required in the future. 
 
4.3. Synthesis of the Synthetic Intermediate 4.5 of DEM30355/A 1.14 via an 
Intramolecular Aldol Condensation Approach 
 The following section describes the synthesis of 4.5, which would be a key 
intermediate in the synthesis of ring A of DEM30355/A 1.14. We envisioned that 
compound 4.5 could be prepared through a halogen-metal exchange reaction of 
arylbromide 4.23 using n-BuLi, followed by DMF trapping. The protection of alcohol 4.24 
with TBDMSCl would produce compound 4.23, whilst the primary alcohol 4.24 could be 
obtained by reducing the previously prepared aldehyde 3.19 (Scheme 4.14). 
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Scheme 4.14: The retrosynthesis of the key synthetic intermediate 4.5. 
 
4.3.1. Reduction of Aldehyde 3.19 Using DIBAL-H 
 The first step in this synthesis of 4.5, includes reducing the previously synthesised 
aldehyde 3.19 to the corresponding alcohol 4.24 using DIBAL-H. We therefore reacted 
3.19 with DIBAL-H in toluene at -78 °C. After 1 hour, the reaction was quenched with 
NH4Cl. The appearance of a new singlet peak in the 
1H NMR of the crude reaction, 
corresponding to two benzylic protons at 4.94 ppm, confirmed the formation of alcohol 
4.24. The purification of the crude reaction mixture by column chromatography gave the 
desired product 4.24 in a moderate yield 41%. We then optimised the reaction condition by 
extending the reaction time to 3 hours, the product 4.24 was obtained in an excellent yield 
98% (Table 4.5). 
 
No. Time (hr) %Yield  
1 1 41 
2 3 98 
Table 4.5: Examination of the reduction of 3.19 to 4.24 using DIBAL-H. 
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 In the next step, we turned our attention to protect the resulting alcohol 4.24 as a 
silyl ether. 
 
4.3.2. Silyl Ether Protection of 4.24 
 We examined the protection of 4.24 with the silylating agent TBDMSCl in the 
presence of imidazole in DCM. After 12 hours the product 4.23 was isolated following 
column chromatography in a high yield 97%.  
 
Scheme 4.15: Protection of the alcohol 4.24 using TBDMSCl. 
 
4.3.3. Halogen-Metal Exchange Reaction of 4.23 
 With compound 4.23 in hand, we examined the synthesis of 4.5 through a halogen-
metal exchange reaction of 4.23 in combination with trapping with DMF. We started our 
investigation by reacting 4.23 with n-BuLi in THF for 30 minutes at -78 °C. The resulting 
aryllithium intermediate was trapped with DMF. We found that quenching the reaction after 
30 minutes gave the desired product 4.5 in 42%. Whereas the yield of 4.5 decreased with 
longer reaction times (Table 4.6).  
 
No. Reaction time after DMF addition %Yield 
1 30 min 42 
2 1 hr 34 
3 3 hr 0 
Table 4.6: Examination of halogen-metal exchanged reaction trapping with DMF. 
 The lower yields observed with longer reaction times were due to the formation of 
an undesired by-product in this reaction. A more in depth discussion of the effect of reaction 
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time of the yield of 4.5 along with an examination of the by-products formed in this reaction 
will be discussed in chapter 5. 
 
4.4. Conclusion 
 In conclusion, this chapter has examined a new synthetic route towards our target 
natural product antibiotic DEM30355/A 1.14 based on the synthesis of two key 
intermediates 4.5 and 4.4. In our work towards 4.4 we have examined a number of 
approaches for the formation of intermediate 4.11, with the oxidative cleavage of acetal 
protected D-mannitol 4.22 followed by addition of 1-propynylmagnesium bromide and a 
subsequent Swern oxidation providing most successful. The synthesis of key intermediate 
4.5 was also examined through a reduction, protection and halogen-metal exchange 
reaction followed by trapping with DMF. 
 
4.5. Future Work 
 The further work would primarily focus on the synthesis of the synthetic 
intermediate 4.6. 
 
Figurer 4.2: Structure of 4.6. 
 Therefore, we firstly aim to complete the synthesis of (Z)-alkene 4.9 through the 
hydrogenation of alkyne 4.11.  
 
Scheme 4.16: Proposed reaction for the synthesis of 4.9. 
 Secondly, we would like to optimise the condition of aldol reaction of 4.18 and 4.17 
to improve the yield of 4.16. The following double protection of 4.16 would provide the 
synthetic intermediate 4.10.  
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Scheme 4.17: Proposed route towards the synthesis of 4.10. 
 After a successful synthesis of 4.9 and 4.10, we wish to investigate the nucleophilic 
addition of anion 4.10 to the prochiral ketone 4.9 to generate 4.8 with a new quaternary 
stereogenic centre. After a selective protection of acetals in 4.8, we would explore the 
synthesis of 4.6, the core structure of ring C of DEM30355/A 1.14, via an intramolecular 
aldol reaction of 4.7(Scheme 4.18). 
 
Scheme 4.18: Proposed route towards the synthesis of 4.6. 
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Chapter 5 
5. Towards The Total Synthesis of (-)-(3R)-5-Hydroxymellein  
5.1. Introduction 
 Alongside our work on the total synthesis of DEM30355/A 1.14, we wanted to 
explore the use of our synthetic approaches to make related bioactive polyketides. We 
chose a target (-)-(3R)-5-hydroxymellein 5.1 as a simple test system to validate our 
synthetic approach to the synthetic intermediate 4.6 (Figure 5.1). 
 
Figure 5.1: The chemical structure of (-)-(3R)-5-hydroxymellein 5.1 and compound 4.6. 
 Our chosen target (-)-(3R)-5-hydroxymellein 5.1 was first isolated by M. de 
Alvarenga et al. in 1978 from unidentified fungus94 and has since been isolated from other 
sources including Septoria (Phaeosphaeria) nodorum Berk95 and Xylaria sp. YC-1096 
fungi. (-)-(3R)-5-Hydroxymellein 5.1 shows antiparasitic activity against the malaria 
causing protozoan parasite Plasmodium falciparum (IC50 = 19 μg/mL) and cytotoxic 
activity against Vero cells (IC50 = 16 μg/mL).97 The total synthesis of racemic 5-
hydroxymellein 5.2 has been achieved previously by Harwood in 1982. This synthesis was 
based around a key Claisen rearrangement of 5-allyloxy-2- hydroxybenzoic acid catalysed 
by trifluoroacetic acid (TFA), followed by a cyclisation of 5.4 to give 5.2 in 32% yield.98  
 
Scheme 5.1: The total synthesis of the racemic 5-hydroxymellein 5.2. 
 In our research we aim to synthesise the enantiomerically pure (-)-(3R)-5-
hydroxymellein 5.1 as it is found in nature. 
 
5.2. Retrosynthesis of (-)-(3R)-5-Hydroxymellein 5.1 
 We envisioned that (3R)-5-hydroxymellein 5.1 could be obtained through the 
demethylation of lactone 5.5 with BBr3. The oxidation of lactol 5.6 could produce the 
corresponding lactone 5.5. Lactol 5.6 would be in an equilibrium with 5.7, thus compound 
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5.7 could be obtained by a selective oxidisation of the primary alcohol of 5.8. A protected 
variant of alcohol of 5.9 could be formed by a halogen-metal exchange reaction of 4.23 
with n-BuLi, to generate the corresponding aryl lithium, followed by a regioselective attack 
on (R)-(+)-propylene oxide 5.10 (Scheme 5.2).  
 
Scheme 5.2: Retrosynthetic analysis of (-)-(3R)-5-hydroxymellein 5.1. 
 Note that (±)-propylene oxide 5.11, rather than (R)-(+)-propylene oxide 5.10, was 
used for experimental optimization throughout the following discussions due to the expense 
of (R)-(+)-propylene oxide. On completion of the synthesis we would plan to repeat these 
steps with (R)-(+)-propylene oxide to make (-)-(3R)-5-hydroxymellein 5.1. 
 
5.3. Examination of Routes towards of (-)-(3R)-5-Hydroxymellein 5.1 
5.3.1. The Halogen-Metal Exchange and Trapping Reactions of 4.23 
 We therefore began our synthetic approach toward the target (3R)-5-
hydroxymellein 5.1 through an examination of the halogen-metal exchange reaction of ((2-
bromo-3,6-dimethoxybenzyl)oxy)(tert-butyl)dimethylsilane 4.23 with n-BuLi in 
combination with trapping with (±)-propylene oxide 5.11 (Scheme 5.3). 
 
Scheme 5.3: Attempted halogen-metal exchange reaction of 4.23 with trapping by propylene oxide 
5.11. 
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 We started our investigation by performing the halogen-metal exchange reaction of 
4.23 with n-BuLi for 30 minutes at -78 °C, followed by the addition of propylene oxide 
5.11 at room temperature. After 2 hours, the 1H NMR of the crude reaction mixture did not 
show the expected peaks for the desired product 5.12. However a new aromatic AB system 
with peaks at 6.91 and 6.77 ppm (d, J = 9.1 Hz) could be observed in the 1H NMR. In 
addition the two peaks corresponding to the two methyl groups had shifted apart to give 
two distinct peaks at 3.71 and 3.87 ppm, and a new broad peak at 2.71 ppm corresponding 
to an OH group was seen. The analysis of this NMR suggested that this new compound did 
not appear to be a simple dehalogation of 4.23 therefore this compound was isolated by 
column chromatography to give 5.13 in a 99% yield. Further analysis of the purified 
compound showed the presence of a signal at 3620 cm-1 in the IR spectrum, which 
confirmed that the molecule contains an OH group. High resolution mass spectrometry of 
5.13 gave a signal at of 305.1544 which corresponds to [M+Na]+. The isotopic profile that 
we would expect for the presence of a bromine atom could not be observed, suggesting the 
bromine had been lost. Based on this analysis we have assigned the structure of 5.13 as 
shown below (Figure 5.2). 
 
Figure 5.2: The structure of the rearranged compound 5.13. 
 We postulated that compound 5.13 was produced as a result of an intramolecular 
[1,4]-silyl migration from the oxygen to the aryl anion, generated by a halogen-metal 
exchange of 4.23 with n-BuLi. This silyl migration is known as a retro-Brook 
rearrangement. The Brook rearrangement was discovered by A. Brook in the late 1950s, it 
is defined as an intramolecular [1,n]-anionic migration of a silyl group from a carbon to an 
oxygen atom in the presence of a strong base.99 The reverse process in which the silyl group 
migrated from an oxygen to a carbon atom is called the retro-Brook rearrangement and it 
was firstly reported by J. Speier at 1952 (Scheme 5.4).100 
Chapter 5 Towards The Total Synthesis of (-)-(3R)-5-Hydroxymellein 
 
 
75 
 
 
Scheme 5.4: Brook and retro-Brook rearrangement. 
 Therefore, our proposed mechanism for the formation of 5.13, via a retro-Brook 
rearrangement, involves the generation of aryllithium 5.14 via a halogen-metal exchange 
reaction of 4.23 with n-BuLi. Then, the reactive aryllithium 5.14 can attack the silicon to 
form the pentacoordinate silicon intermediate 5.15. Intermediate 5.15 can then undergo Si-
O bond cleavage to give the more stable anion 5.16 which is then protonated during the 
work-up with NH4Cl (Scheme 5.5). 
 
Scheme 5.5: Our proposed mechanism for the formation of 5.13 via a retro-Brook rearrangement. 
 
 Interestingly when we re-examined the 1H NMR spectra for the halogen-metal 
exchange reaction of 4.23 followed by trapping with DMF, as described in Chapter 4, we 
also observed the formation of the retro-Brook product 5.13. This provides an explanation 
for the relatively poor yield in our earlier DMF trapping experiments (Table 5.1) 
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No. Time %Yield of 4.5 %Yield of 5.13 
1 30 min 42 28 
2 1 hr 34 55 
3 3 hr 0 99 
Table 5.1: The influence of trapping reaction times on the yield of 4.5 and 5.13. 
 Now that we had a better understanding of the reactivity of 4.23 with BuLi, we 
attempted to repeat the halogen-metal exchange reaction of 4.23 with BuLi and trap with 
5.11 whilst avoiding the competing retro-Brook rearrangement. To do this we examined a 
reduction in the time allowed for the halogen-metal exchange step from 30 to 10 minutes. 
Assuming that the halogen-metal exchange is rapid then an earlier addition of the 
electrophile may help to increase the yield of the desired product 5.12. However, the 1H 
NMR of the crude material still showed only the presence of the rearranged product 5.13. 
This suggests that the retro-Brook rearrangement of the corresponding anion of 4.23 occurs 
faster than the desired intermolecular reaction with propylene oxide 5.11. Therefore, there 
is a need for an alternative protecting group that less susceptible to a retro-Brook 
rearrangement. Thus we chose to protect the alcohol 4.24 with the very bulky 
triisopropylsilyl group, as the increased bulk should slow the undesired retro-Brook 
rearrangement by reducing the rate of attack of the anion onto the silicon centre.101 
 
5.3.2. Protection of Alcohol 4.24 with TIPSCl  
 We therefore examined the protection of alcohol 4.24, through the reaction of 4.24 
with TIPSCl and imidazole in DCM at room temperature. After 12 hours, the desired 
product 5.17 was successfully isolated by column chromatography in a good yield 80%.  
 
Scheme 5.6: The protection of alcohol 4.24 using TIPSCl. 
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5.3.3. Halogen-Metal Exchange Reaction of 5.17 
 After a successful synthesis of TIPS protected 5.17, we carried out a test reaction 
to investigate if a retro-Brook rearrangement would occur in this substrate in the presence 
of n-BuLi. To assist in the investigation of this reaction we used D2O to trap the products. 
We therefore reacted 5.17 with n-BuLi for 30 minutes, then the resulting product was 
trapped with D2O and after 3 hours the reaction was quenched. Two compounds were seen 
in the 1H NMR of the reaction mixture, unreacted starting material was the major product 
and a new compound 5.18 was present. The 1H NMR showed a new AB system (two 
doublets at 6.87 and 6.72 ppm) accompanied by two new singlet peaks at 3.84 and 3.69 
ppm, which indicated two methoxy groups. Comparison of the 1H NMR of 5.18 with that 
of the retro-Brook product 5.13 showed considerable similarity, thus we proposed that this 
reaction has given a 3:1 ratio of unreacted starting material 5.17 to retro-Brook product 
5.18. TBDMS protected alcohol 4.24 was completely consumed after the same reaction 
time to give the retro-Brook product 5.13 in a 99%, thus this suggests that the TIPS 
protecting group undergoes a slower retro-Brook rearrangement than TBDMS.  
 
Scheme 5.7: Examination of the halogen-metal exchange reaction of 5.17. 
 The previous result prompted us to explore halogen-metal exchange reaction of 5.17 
trapping with propylene oxide, anticipating that the slow rearrangement may allow for 
efficient trapping of the aryllithium. 
 
 
Scheme 5.8: Attempted halogen-metal exchange of 5.17 followed by trapping with propylene oxide 
5.11. 
 We therefore examined a halogen-metal exchange reaction of 5.17 with n-BuLi for 
30 minutes, followed by trapping with propylene oxide 5.11. The reaction was quenched 
12 hours later and analyzed by 1H NMR. However, no product was observed, peaks 
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corresponding to starting material could be seen along with those of a second major 
compound, likely to be the dehalogenated species 5.20 (Figure 5.3). Due to the complex 
nature of these reaction, we decided to change the silyl protecting group to an acetal, as this 
would prevent any competing retro-Brook chemistry. 
 
Figure 5.3: The structure of the dehalogetated compound 5.20. 
 
5.3.4. Protection of Aldehyde 3.19 as a Cyclic Acetal 
 Thus we investigated the protection of aldehyde 3.19 with ethylene glycol, 
catalysed by p-TSA. After refluxing the reaction for 4 hours at Dean-Stark apparatus, the 
product 2-(2-bromo-3,6-dimethoxyphenyl)-1,3-dioxolane 5.21 was successfully isolated 
from the crude material by column chromatography in a high 80% yield.  
 
Scheme 5.9: Protection of aldehyde 3.19 as acetal 5.21. 
 
5.3.5. Halogen-Metal Exchange Reaction of Cyclic Acetal 5.21 
 With compound 5.21 in hand, we then investigated the halogen-metal exchange 
reaction of 5.21 with n-BuLi followed by trapping with propylene oxide 5.11. The halogen-
metal exchange step ran for 30 minutes, followed by the addition of 5.11. After 18 hours 
the reaction was quenched.  
 
Scheme 5.10: Attempted halogen-metal exchange and trapping reaction towards 5.22. 
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 The 1H NMR of the crude reaction showed mainly the corresponding dehalogenated 
product, with traces of the desired target 5.22. As the cyclic acetal seemed to be an 
unsuitable protecting group in this reaction we decided to convert aldehyde 3.19 into 
acyclic acetal as an alternative protecting group for aldehyde 3.19. 
 
5.3.6. Protection of Aldehyde 3.19 as an Acyclic Acetal 
 Based on a modified literature procedure, we examined the protection of aldehyde 
3.19 with trimethyl orthoformate in methanol, in the presence of catalytic amount of p-TSA 
and molecular sieves 4 Å.102 The formation of product 5.23 was successfully achieved in 
an excellent yield 96%, after refluxing the reaction for 12 hours. Due to the purity of the 
5.23 formed, no purification was required and the material was used in the subsequent 
reaction directly. 
 
Scheme 5.11: Protection of aldehyde 3.19 with trimethyl orthoformate. 
 
5.3.7. Halogen-Metal Exchange Reaction of Acyclic Acetal 5.23 
 After a successful synthesis of 5.23, we investigated the halogen-metal exchange 
reaction of 5.23 followed by trapping with 5.11. Thus we reacted 5.23 with n-BuLi at -78 
°C. After 30 minutes propylene oxide 5.11 was added and the reaction was warmed to room 
temperature. After 2 hours the reaction was quenched with NH4Cl. The 
1H NMR of the 
crude mixture showed peaks corresponding dehalogenated material and a new set of peaks 
which including a one proton doubletof doublet of quartets at 4.24 ppm, a three proton 
doublet at 1.36 ppm, and two double, doublets at 2.76 and 2.30 ppm all of which are 
consistent with the desired product 5.24 (Figure 5.4). However 5.24 was a minor 
component of the reaction as the yield of isolated product by column chromatography was 
poor 12%. We therefore decided to optimise the reaction condition to improve the yield of 
the product 5.24. We therefore examined extending the reaction time for the trapping of 
5.11, following the halogen-metal exchange. After 30 hours, the reaction was quenched and 
the crude material was purified by column chromatography to give the desired product 5.24 
in a moderate yield of 36%.  
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Scheme 5.12: The synthesis of 5.24 via H-M exchange reaction. 
 
  
Figure 5.4: The 1H NMR spectrum of 5.24. 
 We then attempted to further optimise the reaction conditions using Lewis acid 
additives to accelerate the rate of the ring opening reaction of propylene oxide 5.11. We 
therefore repeated the halogen-metal exchange reaction of 5.23 and examined the effects 
of adding 5.11 and then boron trifluoride diethyl etherate at low temperature. After running 
this reaction several times under different conditions the desired product 5.24 was not 
observed in the 1H NMR of the crude reaction and a complex mixture of by-products was 
seen. We then investigated the use of other Lewis acids, thus the reaction was repeated as 
previously with the addition of CeCl3 during the ring opening step. However, after 2 hours 
only the dehalogenated product could be observed (Table 5.2). 
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No. Reaction Condition Additives %Yield  
1 n-BuLi, THF, -78°C, 20 min 
then 5.11, 2 hr, r.t. 
- 12 
 
2 n-BuLi, THF, -78°C, 20 min 
then 5.11, 30 hr, r.t. 
- 36 
3 n-BuLi, THF, -78°C, 20 min 
then 5.11, 2 hr, r.t.. 
BF3.O(C2H5)2 No product, complex 
mixture of by-
products were 
observed. 
4 n-BuLi, THF, -78°C, 20 min 
then 5.11, 2 hr, -78 °C. 
BF3.O(C2H5)2 No product, complex 
mixture of by-
products were 
observed. 
5 n-BuLi, THF, -78°C, 10 min 
then 5.11, 2 hr, -78 °C. 
BF3.O(C2H5)2 No product, complex 
mixture of by-
products were 
observed. 
6 n-BuLi, THF, -78°C, 20 min 
then 5.11, 2 hr, r.t. 
CeCl3 No product, mainly 
dehalogenated 
product observed. 
Table 5.2: Examination of the H-M exchange reaction of 5.23 with trapping by propylene oxide 5.11. 
 Despite screening a number of Lewis acid additives, the best conditions for the 
formation of 5.24 involved long reaction times for the ring opening of propylene oxide. 
However, this approach allowed us access to sufficient 5.24 for us to examine the next 
steps in our planned synthesis. 
 
5.3.8. Deprotection of Acetal 5.24 
 The next step involved the planned removal of the acetal protecting group in 5.24 
in order to produce the corresponding lactol 5.25, which could in turn be subsequently 
oxidised and deprotected to give 5-hydroxymellein. 
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Scheme 5.13: Proposed acetal hydrolysis with acid. 
 We examined the hydrolysis of 5.24 using 0.1 M of aqueous HCl in acetonitrile. 
The reaction was monitored by TLC. After 12 hours only starting material could be 
observed by TLC and 1H NMR. We then repeated the reaction using 0.2 M of aqueous HCl 
in 1,4-dioxane, however again starting material was recovered with no product was 
observed. 
 Next, we turned our attention to examining an alternative acidic condition for the 
cleavage of the acetal 5.24 using trifluoroacetic acid (TFA). We therefore reacted 5.24 with 
TFA in the presence of H2O at room temperature. After 30 minutes the starting material 
was consumed and new two spots were formed in the TLC plate. The 1H NMR of the crude 
reaction showed the presence of new peaks corresponding to lactol 5.25 as a minor 
component along with the related dehalogenated product. Purification of the crude reaction 
mixture by column chromatography gave the desired lactol 5.25 in 28%. 
 Next, to improve the yield of this step we examined a method reported by Sun for 
acetal deprotection under neutral condition using a catalytic amount of molecular iodine in 
acetone.103 We therefore carried out a reaction of 5.24 with iodine in acetone at room 
temperature. The reaction was quenched with sodium thiosulfate after 45 minutes. After 
chromatography the 1H NMR of the isolated product showed the presence of two benzylic 
peaks at 5.49 and 5.45 ppm (d, J = 3.5 Hz, 1H) and two sets of peaks at 3.03 (dd, J = 14.8, 
3.5 Hz, 1H), 2.89 (dd, J = 14.8, 10.2 Hz, 1H) and 2.80 (dd, J = 17.2, 3.4 Hz, 1H) 2.34 (dd, 
J = 17.2, 10.8 Hz 1H) corresponding to two benzylic methylene groups both in a 1:1 ratio. 
This is consistent with the presence of both of the possible diastereomers of lactol 5.25 
(Figure 5.5). 
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Figure 5.5: The 1H NMR spectrum of 5.25. 
 Further analysis was carried out to confirm the structure of 5.25. High resolution 
mass spectroscopy showed a signal at 207.1060 which indicates the presence of the 
corresponding oxonium arising from loss of water from 5.25 (Figure 5.6) 
 
Figure 5.6: The HRMS of lactol 5.25. 
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 Crystals were then obtained through slow diffusion of petrol into a solution of 5.25 
in DCM. Interestingly, the single crystal X-ray analysis of the formed crystals showed the 
presence of dimeric diacetal 5.27 instead of the expected lactol 5.25 (Figure 5.7). 
 
Figure 5.7: Crystal structure of (1S,1'S,3S,3'S)-5.27. 
 
 The crystal contains a racemic 1:1 mixture of the (1S,1'S,3S,3'S)-5.27 and the 
(1R,1'R,3R,3'R)-5.27 (Figure 5.8). 
 
Figure 5.8: Crystal packing diagram showing a pair of enantiomers of 5.27. 
 
 Interestingly despite the presence of both the possible diastereomers in the 1H NMR 
of lactol 5.24, the crystal structure only contains dimers with (1S,1'S,3S,3'S) and the 
(1R,1'R,3R,3'R) stereochemistry. The dimer is likely formed through a condensation 
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reaction between two lactols. The observed stereochemistry in the crystal maybe due to a 
preferential crystallisation of the (1S,1'S,3S,3'S)/(1R,1'R,3R,3'R) diastereomer. 
 Although this approach was promising, due to the low yields in the formation of 
5.24 we decided to examine in parallel an alternative protecting group strategy employing 
a methyl ether. 
 
5.3.9. Protection of Alcohol 4.24 with Methyl Iodide  
 We also investigated the protection of alcohol 4.24 as a methyl ether using methyl 
iodide and sodium hydride in THF at room temperature. After 12 hours, product 5.28 was 
successfully isolated by column chromatography in a good yield 88%.  
 
Scheme 5.14: Protection of alcohol 4.24 as a methyl ether. 
 
5.3.10. Halogen-Metal Exchange Reaction of Methyl Ether 5.28 
 With 5.28 in hand, we examined the formation of 5.29 via a halogen-metal 
exchange reaction followed by trapping with 5.11. We reacted 5.28 with n-BuLi at -78 °C 
prior to the addition of propylene oxide 5.11. After 2 hours the reaction was quenched and 
the 1H NMR of the crude showed the formation of product 5.29, along with some 
dehalogeated, with an isolated yield of 31%. We therefore optimised the reaction conditions 
to improve the yield of 5.29 by extending time for the reaction with propylene oxide 5.11. 
The reaction was quenched 4 hours following the addition of 5.11 and the yield of 5.29 had 
increased significantly to 78% (Table 5.3). 
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No.  Reaction time following addition of 5.11 %Yield 
1 2 hr 31 
2 4 hr 78 
Table 5.3: Examination of the halogen metal exchange reaction of 5.26 followed by trapping with 
5.11. 
 
 After the positive outcomes that obtained from this reaction, we aimed to deprotect 
5.29 in order to produce the corresponding diol 5.30. 
 
5.3.11. Deprotection of Methyl Ether 5.29 
 We therefore examined the cleavage of methyl ether 5.29. We firstly looked at the 
use of demethylating agent BBr3 in DCM. 
 
Scheme 5.15: Proposed cleavage of methyl ether 5.29. 
 We started our investigation through the reaction of 5.29 with BBr3 at -78 °C. After 
30 minutes the reaction was quenched with cold saturated aqueous solution NaHCO3. The 
appearance of two new diastereomeric benzylic peaks at 4.76 (d, J = 9.7 Hz, 1H) and 4.70 
(d, J = 9.7 Hz, 1H) ppm in the 1H NMR confirmed the formation of a new compound 
(Figure 5.9). 
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Figure 5.9: The 1H NMR for the reaction product of 5.29 with BBr3.  
 The IR spectra however showed that no OH groups were present. The high 
resolution mass spectrometry showed a signal at 209.1172 which corresponds to a 
molecular formula of C12H17O3 which suggests that the product was not the desired diol 
5.30. Based on the previous analysis, we therefore propose that the reaction of 5.29 with 
BBr3 gave compound 5.31 very cleanly in a 99% yield (Figure 5.10).  
 
Figure 5.10: Structure of 5.31. 
 
 We propose that 5.31 was formed through a Lewis acid activation of the methoxy 
group followed by an intramolecular substitution by the hydroxyl to form the observed 5.31 
ether. In parallel, we also examined another method for the deprotection of methyl ether 
5.29 using in situ generated trimethylsilyl iodide.104 Based on a modified literature 
procedure, we reacted 5.29 with sodium iodide and trimethylsilyl chloride in acetonitrile in 
the presence of water at 40°C.105 After 2 hours the crude reaction mixture was purified by 
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column chromatography. The 1H NMR spectrum of the isolated product was identical to 
compound 5.31 suggesting that a very similar reaction had occurred. 
 
Scheme 5.16: Synthesis of 5.31 via the cleavage of 5.29 with TMSI. 
 Despite failing to make our target molecule 5.30, we have successfully synthesised 
compound 5.31 through the demethylation of 5.29 following two different methods using 
the Lewis acid BBr3 and TMSI both in high yield (Table 5.4). 
 
No. Demethylating 
Agent 
Reaction Time Product %Yield 
1 BBr3 30 min 
 
 
99 
2 TMSI 2 hr 
 
97 
Table 5.4: Examination of the cyclisation 5.29 using BBr3 and TMSI. 
 
5.3.12. Oxidation of the Benzyl Ether 5.31 
 Compound 5.31, despite being an unexpected product, could still prove useful in 
the formation of 5-hydroxymellein and it analogues if the benzylic position adjacent to 
oxygen could be selectively oxidised. Thus, we attempted to oxidise benzyl ether 5.31 to 
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produce the corresponding lactol 5.25 and/or lactone 5.32, an analogue of 5-
hydroxymellein 5.2. 
 
Scheme 5.17: Proposed oxidation reaction of benzyl ether 5.31. 
 We have screened a number of reaction conditions using several different oxidising 
agents including: 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ), meta-chloroperbenzoic 
acid; (m-CPBA), manganese dioxide (MnO2) and a combination of potassium 
permanganate and manganese dioxide (KMNO4/MnO2) using different solvents under 
variable temperatures.106,107,108,109 However, none of these conditions gave the desired 
products 5.25 or 5.32 (Table 5.5). 
 
No. Oxidising 
Agents 
Reaction 
Condition 
Reaction Outcomes Product 
1 DDQ toluene 
4 hr, r.t. 
Starting material 
recovered 
- 
2 DDQ toluene 
6 hr, reflux 
No product, starting 
material was 
decomposed  
- 
3 DDQ DCM/MeOH 
24 hr, r.t. 
Starting material 
recovered 
- 
 
 
4 DDQ DCM/MeOH 
48 hr, r.t. 
Ring opening of 5.31 
by MeOH reproducing 
5.29 with minor 
unidentified products 
observed, the yield of 
isolated 5.29 is 17%  
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5 m-CPBA DCM 
4 hr, r.t. 
No product was 
observed, starting 
material was 
decomposed 
- 
6 MnO2 DCM 
12 hr, r.t. 
Ring opening of 5.31 
by H2O to produce diol 
5.30 in 26% yield 
 
7 KMNO4/MnO2 DCM 
6 hr, r.t. 
No product was 
observed, starting 
material was 
decomposed 
- 
 Table 5.5: Examined reactions conditions for the oxidation of benzyl ether 5.31. 
 Interestingly, we observed in a number of cases the ring opening of the ether 5.31 
by MeOH during the oxidation reaction with DDQ to reproduce 5.29, and by H2O in the 
case of using MnO2 to give the desired diol 5.30.  
 Due to the time constraint the investigation on the oxidation of benzyl ether 5.31 
will be continued in the future.  
 
5.4. Conclusion 
 In conclusion, we investigated several synthetic routes towards the total synthesis 
of (-)-(3R)-5-hydroxymellein 5.1 based on the approach we have previously developed in 
chapter 4 for producing the aromatic ring of DEM30355/A 1.14. Using racemic propylene 
oxide 5.11 as a test reagent, we have successfully proved that the chiral centre can be 
created through the halogen-metal exchange reaction of arylbromides followed by (±)-
propylene oxide trapping in the presence of certain protecting groups. In case of using silyl 
protecting groups, the Brook rearrangement occurred during H-M exchange reaction due 
to the slow rate of the ring opening reaction of 5.11. The best substrate for our halogen-
metal exchange/trapping strategy was methoxy ether 5.28. Despite difficulties in 
deprotecting the methyl ether, due to the unexpected formation of cyclic ethers, in our 
attempts to oxidise ether 5.31 we have observed ring opening to the desired diol, which has 
the potential for further oxidation/deprotection to give 5-hydroxymellein. 
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5.5. Future Work 
Our aim is to complete the total synthesis of 5-hydroxymellein 5.2 through use of 
the two efficient synthetic routes we developed using dimethyl acetal and methoxy ether as 
protecting groups. 
Following in our synthetic route whereby dimethyl acetal is used as a protecting 
group, we plan to improve the yield of 5.24 by optimising the halogen-metal exchange 
reaction conditions, and thus complete this route towards our target natural product. 
 
Scheme 5.18: Towards the total synthesis of 5-hydroxymellein 5.2 using methoxy ether protecting 
group. 
 If the halogen metal exchange and trapping in the first route could not be improved 
then we would look to continue our alternative approach. Thus in the second synthetic 
route, based upon the use of methoxy ether as a protecting group, the reaction conditions 
for the deprotection of methoxy ether 5.29 could be optimised to produce diol 5.30, through 
use of a of Lewis acid and water. The total synthesis of 5-hydroxymellein would then be 
completed through the oxidation of diol 5.30 to produce lactone 5.32, followed by the 
demethylation of the phenolic hydroxyl groups. 
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Scheme 5.19: Towards the total synthesis of 5-hydroxymellein 5.2 using dimethyl acetal protecting 
group. 
 Next, in order to synthesise an enantiopure (-)-(3R)-5-hydroxymellein 5.1, it would 
be necessary to repeat the synthesis with (R)-(+)-propylene oxide 5.10. Additionally, in a 
similar way, the synthesis of (-)-(3S)-5-hydroxymellein enantiomer 5.33 could be achieved 
by using (S)-(+)-propylene oxide (Figure 5.11).110  
 
 
Figure 5.11: Structures of (-)-(3R)-5-hydroxymellein 5.1 and (-)-(3S)-5-hydroxymellein 5.33. 
 With the development of a successful synthetic route to the natural product, a 
number of 5-hydroxymellein analogues could be generated. Given the activity of 5-
hydroxymellein against malaria causing protozoan Plasmodium falciparum, we wish to 
investigate the biological activity these analogues, including the related natural products 
mellein 5.34, 4-hydroxymellein 5.35, 6-hydroxymellien 5.36 and 7-hydroxymellein 5.37 
(Figure 5.12). 
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Figure 5.12: Suggested analogues of 5-hydroxymellein. 
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Chapter 6 
6. Experimental Section 
6.1. Experimental Information  
Reagents and chemicals were purchased from commercial suppliers (Sigma Aldrich, Alfa 
Aesar and TCI) and used as received. All air and water sensitive reactions were performed 
under a nitrogen atmosphere using standard Schlenk line techniques. Solvents were 
distilled under an atmosphere of nitrogen prior to use. THF, diethyl ether and toluene were 
distilled from sodium wire in the presence of benzophenone. DCM and toluene were 
distilled from calcium hydride. Thin layer chromatography (TLC) was visualized with 
ultraviolet light (UV) (λ = 235 nm). Melting points were determined in open glass capillary 
tubes on a Stuart SMP3 melting point apparatus. Infra-red (IR) spectra were obtained as 
neat samples using a Varian 800 FT-IR Scimitar Series spectrometer scanning from 4000-
600 cm-1. Flash column chromatography was used for purification (Merck Kieselgel 60 
silica gel).1H and 13C NMR spectra were recorded directly with a Jeol ECS-400 MHz 
spectrometer operating at 399.78 and 100.53MHz respectively, or Bruker Avance 300 MHz 
spectrometer operating at 300.13 and 75.47 MHz respectively. Chemical shift are quoted 
in part per million (ppm) relative to tetramethylsilane (TMS). Mass spectrometry analyses 
carried out using Micromass LCT Premier Mass Spectrometer in Electron Spray (ES) mode 
or he EPSRC National Mass Spectrometry Service Centre, Swansea. X-ray diffraction data 
was obtained on an Oxford Diffraction Gemini.  
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Diethyl 2-hydroxy-2-(3-oxobut-1-en-2-yl)malonate 2.18 
 
Into a 25 mL round bottom flask, 1,4-diazabicyclo[2.2.2]octane 2.20 (56.08 mg, 0.50 
mmol) was dissolved in THF (5 mL) then 3-butene-2-one 2.19 (0.407 mL, 5.00 mmol) and 
diethyl ketomalonate (0.762 mL, 5.00 mmol) were added respectively. The reaction 
mixture was stirred for 4 days at room temperature. DCM (25 mL) was added to the reaction 
mixture,. then the organic layer washed with diluted HCl (25 mL, 1M) and sodium 
bicarbonate (50 mL). Organic layers were combined, dried over anhydrous MgSO4 and the 
solvent was evaporated under reduced pressure. The crude material was subjected to silica 
gel column chromatography (petroleum ether 40/60:diethyl ether 1:1) to give product 2.18 
(0.12 g, 0.49 mmol, 98%) as a pale yellow oil. 
Rf 0.2 (vanillin TLC stain active, petroleum ether 40/60:diethyl ether 1:1). 
1H NMR (300 MHz, CDCl3) δH 6.32 (d, J = 1.0 Hz, 1H, C=CH2), 6.21 (d, J = 1.0 Hz, 1H, 
C=CH2), 4.42 – 4.21 (q, J = 7.1 Hz, 4H, CH2-CH3), 2.41 (s, 3H, O=C-CH3), 1.31 (t, J = 
7.1 Hz, 6H, CH2-CH3).  
13C NMR (101 MHz, CDCl3) δC 198.06 (H3C-C=O), 169.02 (O-C=O), 145.42 (C=CH2), 
128.12 (C=CH2), 79.21(C-OH), 62.96 (O-CH2-CH3), 26.38 (H3C-C=O), 13.98(CH2-CH3). 
MS (ESI) [M+Na]+ calculated for C12H18O6Na: 267.0845, found: 267.0852. 
IR (neat): υ max/cm-1 3445, 2981, 1737, 1633. 
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2-Iodo-1,4-dimethoxybenzene 2.28 
 
Into a 50 cm3 round bottomed flask, 1,4-dimethoxybenzene 2.29 (0.276 g, 2.00 mmol), 
(diacetoxyiodo) benzene (0.708 g, 2.20 mmol) and iodine (0.507 g, 2.00 mmol) were dissolved 
in 5 mL of acetonitrile. The reaction was stirred for 24 hours at room temperature. The reaction 
mixture was diluted with DCM (10 mL). The organic layer was washed with a saturated 
solution of sodium thiosulfate (2×15 mL) and brine (15 mL). The combined organic extracts 
were dried over MgSO4, filtered and the solvent was removed under reduced pressure. The 
resulting crude product was purified by silica gel column chromatography (petroleum ether 
40/60:diethyl ether 7:3) to give 2.28 (0.410 g, 1.60 mmol, 78%) as a yellow oil. 
Rf  0.55 (UV active, petroleum ether 40/60:diethyl ether 7:3). 
1H NMR (300 MHz, CDCl3) δH 7.35 (d, J = 3.0 Hz, 1H, C3H), 6.87 (dd, J = 9.1, 3 Hz, 1H, 
C5H), 6.76 (d, J = 9.1 Hz, 1H, C6H), 3.83 (s, 3H, O-CH3), 3.76 (s, 3H, O-CH3).  
13C NMR (101 MHz, CDCl3) δC 154.32 (O-C-CH3), 152.76 (O-C-CH3), 124.87 (C-Ar), 
114.84 (C-Ar), 111.65 (C-Ar), 86.83 (C-Ar), 57.07(O-CH3), 56.02 (O-CH3).  
MS (ESI) [M+Na]+ calculated for C8H9O2INa: 286.9520, found: 286.9522.  
IR (neat): υ max/cm-1 1607, 1530, 1436. 
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1-(Triphenylphosphoranylidene)propan-2-one 2.31 
(2-Oxopropyl)triphenylphosphonium chloride 2.33 
 
Into a 250 mL round bottom flask, triphenylphosphine 2.35 (6.55 g, 25.0 mmol) was dissolved 
in toluene (100 mL). Chloroacetone 2.34 (1.99 mL, 25.0 mmol) was added then the reaction 
mixture was refluxed for 24 hours. Precipitated phosphonium chloride salt was filtered to give 
2.33 (6.88 g, 19.3 mmol, 78%). 
 
Into a 250 mL round bottom flask, phosphonium chloride salt 2.33 (6.88 g, 19.0 mmol) was 
dissolved in water (100 mL) then DCM (60 mL) was added to the solution. The solution was 
made alkaline by the dropwise addition of NaOH (25 mL, 1M) then the reaction was stirred 
for 1 hour. The organic layer was separated and the aqueous layer was washed with DCM 
(2×25 mL). The organic layers were combined, dried with MgSO4, filtered and the solvent was 
removed under reduced pressure to give the desired product 2.31 (6 g, 18.0 mmol, 75%). The 
product 2.33 (4.86 g, 15.3 mmol, 61%) was recrystallized from toluene (65 mL) as yellow 
crystals. 
mp 210-211°C (lit: 210-211°C).111 
Rf  0.3 (UV active, petroleum ether 40/60:diethyl ether 1:1). 
1H NMR (400 MHz, CDCl3) δH 3.68 (d, 1H, J(P) = 27 Hz), 2.07 (s, 3H), 7.72 – 7.38 (m, 15H).  
13C NMR (101 MHz, CDCl3) δC 191.00, 133.10, 132.03, 128.95, 127.79, 51.23, 28.66.  
MS (ESI) [M+Na]+ calculated for C8H9O2INa: 286.9511, found: 286.9514. 
IR (neat): υ max/cm-1 3050, 2989, 1538.  
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(E)-4-(2,5-Dimethoxyphenyl)but-3-en-2-one 2.30 
 
In a 250 mL round bottom flask, 1-(triphenylphosphoranylidene)propan-2-one 2.31 (1.59 g, 
5.00 mmol) was added into a solution of 2,5-dimethoxybenzaldehyde 2.32 (0.83 g, 5.00 mmol) 
in DCM (50 mL). A drying tube was connected to the condenser then the reaction was refluxed 
for 48 hours. The reaction mixture was cooled to room temperature then the solvent was 
removed under reduced pressure. Pre-column (diethyl ether:petroleum ether 40/60 7:3) was 
used to remove Ph3P=O. Collected fractions was combined then the solvent was removed 
under reduced pressure. The resulting crude product was purified by silica gel column 
chromatography (petroleum ether 40/60:diethylether 7:3) to give 2.30 (0.70 g, 3.39 mmol, 
68%) as a yellow powder.  
mp: 49-50 °C (lit. 48-50 °C).112 
Rf 0.47 (UV active, petroleum ether 40/60 – diethyl ether, 7:3). 
1H NMR (300 MHz, CDCl3) δH 7.87 (d, J = 16.5 Hz, 1H, C3H), 7.09 (d, J = 3.0 Hz, 1H, C6'H), 
6.94 (dd, J = 9.1, 3.0 Hz, 1H, C4'H), 6.87 (d, J = 9.1 Hz, 1H, C3'H), 6.72 (d, J = 16.5 Hz, 1H, 
C4H), 3.87 (s, 3H, O-CH3), 3.80 (s, 3H, O-CH3), 2.41 (s, 3H, C1H). 
13C NMR (101 MHz, CDCl3) δC 199.19 (C2), 153.63 (C2'), 152.83 (C5'), 138.59 (C3), 127.97 
(C4), 123.92 (C-Ar), 117.69 (C- Ar), 112.59 (C- Ar), 112.49 (C-Ar), 56.16 (O-CH3), 55.85 (O-
CH3), 27.20 (C
1). 
MS (ESI) [M+Na]+ calculated for C12H14O3Na: 229.0801, found: 229.0806. 
IR (neat): υ max/cm-1 3004, 2838, 1668. 
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2-(2,5-Dimethoxyphenyl)-1,3-dioxolane 3.12 
 
In a 50 cm3 round bottomed flask, 2,5-dimethoxybenzaldehyde 2.32 (0.830 g, 5.00 mmol) and 
p-toluenesulfonic acid monohydrate (50 mg, 0.30 mmol) were dissolved in toluene (15 mL) 
followed by the addition of ethylene glycol (8.36 mL, 150 mmol). The mixture was refluxed 
for 4 hours in a Dean-Stark apparatus. The reaction mixture was allowed to cool to room 
temperature, diluted with ethyl acetate (20 mL). The organic layer was washed with a saturated 
aqueous solution of Na2CO3 (2×10 mL) and brine (20 mL), dried over Na2SO4, filtered and the 
solvents were removed under reduced pressure. The crude material was purified by silica gel 
column chromatography (petroleum ether 40/60:diethyl ether 7:3) to give product 3.12 (0.901 
g, 4.29 mmol, 86%) as a colourless oil. 
Rf :0.25 (UV active, petroleum ether 40/60:diethyl ether, 7:3). 
1H NMR (400 MHz, CDCl3) δH 7.11 (d, J = 3.0 Hz, 1H, C6'H), 6.86 (dd, J = 9.1, 3.0 Hz, 1H, 
C4'H), 6.82 (d, J = 9.1 Hz, 1H, C3'H), 6.12 (s, 1H, C2H), 4.15 – 4.08 (m, 2H, C1H), 4.08 – 3.99 
(m, 2H, C3H), 3.82 (s, 3H, O-CH3), 3.77 (s, 3H, O-CH3). 
13C NMR (101 MHz, CDCl3) δC 153.64 (C2'), 152.02 (C5'), 126.77 (C- Ar), 115.38 (C- Ar), 
112.23 (C-Ar), 112.16 (C- Ar), 99.23 (C2), 65.40 (C1,3), 56.38 (O-CH3), 55.88 (O-CH3).  
MS (ES+) calculated for C11H14O4Na: 210.0936; observed: 233.0942. 
IR (neat): υ max/cm-1 2890, 2998, 2790. 
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2-Bromo-3,6-dihydroxybezaldehyde 3.20 
 
In a dark 250 mL round bottom flask, 2,5-dihydroxybenzaldehyde 3.21 (3.453 g, 25.0 mmol) 
was dissolved in 100 mL of chloroform. Bromine (1.33 mL, 26.0 mmol) was added dropwise 
over 30 minutes then the reaction was stirred for 2.5 hours at room temperature. The reaction 
was washed with a saturated solution of Na2S2O3 (8×20 mL) to remove excess bromine. The 
combined organic layers were separated, dried over Na2SO4, filtered then the solvent was 
removed under reduced pressure to afford product 3.20 (5.403 g, 24.9 mmol, 99%) as a yellow 
powder. 
mp 130-130.5 °C (lit. 123-125 °C).79 
Rf 0.22 (UV active, petroleum ether 40/60 – diethyl ether, 7:3). 
1H NMR (300 MHz, CDCl3) δH 11.67 (s, 1H, O=C-H), 10.29 (s, 1H, OH), 7.26 (d, J = 9.1 Hz, 
1H, C5H), 6.94 (d, J = 9.1 Hz, 1H, C4H), 5.39 (s, 1H, OH).  
13C NMR (101 MHz, CDCl3) δC 196.92 (C=O), 158.07 (C6), 145.0 (C3), 125.42 (C- Ar), 
118.62 (C- Ar), 116.05 (C- Ar), 111.80 (C- Ar).  
HRMS (pNSI): calculated for C7H5BrO3: 218.9474; observed: 218.9475.  
IR (neat): υ max/cm-1 3515, 3259, 1633. 
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1,7-Dibromo-6H,12H-6,12-epoxydibenzo[b,f][1,5]dioxocine-2,8-diol 3.31 
 
mp 232-233.5 °C. 
Rf : 0.2 (UV active, petroleum ether 40/60:diethyl ether 1:1). 
1H NMR (400 MHz, CDCl3) δH 6.98 (d, J = 9.1 Hz, 1H), 6.84 (d, J = 9.1 Hz, 1H), 6.36 
(s, 1H), 5.28 (s, 1H). 
 
13C NMR (101 MHz, CDCl3) δC 156.88, 147.38, 131.54, 118.44, 117.23, 108.63, 89.64. 
 
IR (neat): υ max/cm-1 3407, 1588. 
  
Chapter 6 Experimental Section 
 
 
102 
 
Bromo-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-6-hydroxybenzaldehyde 3.33 
 
Into a 50 mL round bottom flask, 2-bromo-3,5-dihydroxybenzaldehyde 3.20 (1 g, 4.61 mmol) 
was dissolved in DCM (20 mL). Imidazole (0.470 g, 6.93 mmol) and tert-butyldimethylsilyl 
chloride (0.972 g, 6.54 mmol) were added then the reaction mixture was stirred for 1 hour at 
room temperature. The reaction mixture was poured into water (20 mL) and the product was 
extracted with ethyl acetate (2 x 10 mL). Combined organic layers washed with brine (40 mL) 
dried over MgSO4 and filtered, then the solvent was removed under reduced pressure. The 
resulting crude material was purified by silica gel column chromatography (petroleum ether: 
diethyl ether 25:1) to provide desired product 3.33 (0.626 g, 1.89 mmol, 41%) as a yellow 
powder. 
mp 42-44 °C (lit. 42-45°C).79 
Rf  0.5 (UV active, petroleum ether 40/60 – diethyl ether, 25:1). 
1H NMR (300 MHz, CDCl3) δH 11.73 (s, 1H), 10.39 (s, 1H), 7.09 (d, J = 9.1 Hz, 1H), 6.86 (d, 
J = 9.1, 1H), 1.07 (s, 9H), 0.26 (s, 6H). 
13C NMR (101 MHz, CDCl3) δC 198.39, 176.45, 158.47, 129.23, 118.66, 118.01, 117.64, 
25.82, 18.43, -4.09. 
MS (ESI) [M+Na]+ calculated for C13H19BrO3SiNa: 331.2801, found: 331.2804.  
IR (neat): υ max/cm-1 3307, 2928, 1651, 1462. 
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2-Bromo-3-((tert-butyldimethylsilyl)oxy)-6-methoxybenzaldehyde 3.34  
 
In a Schlenk flask, 2-bromo-3-((tert-butyl dimethylsily)oxy)-6-hydroxybenzaldehyde 3.33 
(0.331 g, 1.00 mmol) was dissolved in THF (10 mL). Potassium carbonate (2.764 g, 20 mmol) 
and methyl iodide (0.184 mL, 3.00 mmol) were added then the reaction was heated at 40 °C 
for 24 hours. The reaction mixture was poured into water (20 mL) and the product was 
extracted with ethyl acetate (2 x 20 mL). The combined organics extracts were washed with 
brine (50 mL), dried over anhydrous MgSO4, filtered and the solvent was removed under 
reduced pressure. The resulting crude material was purified by silica gel column 
chromatography (petroleum ether 40/60: diethyl ether 7:3) to give 3.34 (0.201 g, 0.58 mmol, 
58%) as a white powder. 
mp 68-69.5 °C (lit. 67-69 °C).79  
Rf 0.47 (UV active, petroleum ether 40/60:diethyl ether 7:3).  
1H NMR (300 MHz, CDCl3) δH 10.15 (s, 1H), 6.80 (d, J = 9.1 Hz, 1H), 6.62 (d, J = 9.1 Hz, 
1H), 3.63 (s, 3H), 0.81 (s, 9H), 0.01 (s, 6H).  
13C NMR (101 MHz, CDCl3) δC 191.16, 155.83, 147.11, 124.73, 118.03, 114.81, 111.56, 
56.63, 25.85, 18.47, -4.12. 
IR (neat): υ max/cm-1 2945, 2927, 1695. 
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2-Bromo-6-hydroxy-3-methoxybenzaldehyde 3.35 
 
In a 100 mL round bottom flask, 2-bromo-3,6-dihydroxybenzaldehyde 3.20 (0.217 g, 1.00 
mmol) was dissolved in methanol (30 mL). Sodium methoxide (0.118 g, 2.20 mmol) and 
methyl iodide (0.124 mL, 2.20 mmol) were added then the reaction was refluxed for 24 
hours. Methanol was removed under reduced pressure to give black residue. The resulting 
residue dissolved in ethyl acetate (10 mL), and then the organic layer was washed with 
water (10 mL). The organic layer dried over anhydrous MgSO4, filtered then the solvent 
was removed under reduced pressure. The crude was purified by silica gel chromatography 
(petroleum ether 40/60: diethyl ether 4:1) to give 3.35 (18 mg, 0.08 mmol, 8%) as yellow 
crystals. 
mp 75-76.5 °C. 
Rf  0.6 (UV active, petroleum ether 40/60:diethyl ether 4:1). 
1H NMR (300 MHz, CDCl3) δH 11.59 (s, 1H), 10.43 (s, 1H), 7.20 (d, J = 9.1 Hz, 1H), 6.96 
(d, J = 9.1, 1H), 3.91 (s, 3H,). 
13C NMR (101 MHz, CDCl3) δC 198.5, 157.9, 149.6, 123.4, 117.9, 117.5, 116.4, 57.5. 
IR (neat): υ max/cm-1 2840, 1650, 1560, 1467, 1280, 1170. 
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2-Bromo-6-hydroxy-3-methoxybenzaldehyde 3.35 
 
In a Schlenk flask, 2-bromo-3,6-dihydroxybenzaldehyde 3.30 (0.217 g, 1.00 mmol) and 
trimethyloxonium tetrafluoroborate (0.477 g, 3.20 mmol) were dissolved in DCM (5 mL). At 
0 °C, N,N-diisopropylethylamine (0.52 mL, 3.00 mmol) was added. The reaction mixture was 
allowed to stir for 36 hours at room temperature. The mixture was diluted with DCM (10 mL), 
washed with saturated solution of sodium bicarbonate (2×15 mL). The combined organic 
layers were washed with brine (15 mL), dried over MgSO4, filtered and the solvent was 
removed under reduced pressure. The resulting crude material was purified by silica gel 
column chromatography (petroleum ether 40/60:diethyl ether 4:1) to produce 3.35 (0.104.g, 
0.38 mmol, 45%) as a yellow powder. 
mp 75-76.5 °C. 
Rf  0.5 (UV active, petroleum ether 40/60:diethyl ether 1:1). 
1H NMR (300 MHz, CDCl3) δH 11.59 (s, 1H), 10.43 (s, 1H), 7.20 (d, J = 9.1 Hz, 1H), 6.96 
(d, J = 9.1, 1H), 3.91 (s, 3H,). 
13C NMR (101 MHz, CDCl3) δC 198.5, 157.9, 149.6, 123.4, 117.9, 117.5, 116.4, 57.5. 
IR (neat): υ max/cm-1 3352, 1560. 
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2-Bromo-3,6-dimethoxybenzaldehyde 3.19 
 
In a Schlenk flask, 2-bromo-3,6-dihydroxybenzaldehyde 3.30 (3.255 g, 15.0 mmol), 
potassium carbonate (41.46 g, 300 mmol) and tetrabutylammonium bromide (0.483 g, 1.50 
mmol) were dissolved in THF (150 mL). Methyl iodide (5.58 mL, 90.0 mmol) and DMF 
(15 mL) were added and the reaction was stirred for 24 hours at 40 °C. The reaction mixture 
was cooled down and filtered through sintered glass. The filtrate was washed with water 
(75 mL) and the product was extracted with DCM (2×75 mL). The combined organic layers 
were dried over Na2SO4, filtered and the solvents were removed under reduced pressure. 
The crude material was subjected to silica gel column chromatography (petroleum ether 
40/60:diethyl ether 1:1) to give 3.19 (2.752 g, 11.2 mmol, 75 %) as colourless crystals.  
mp 101-102 °C. 
Rf 0.5 (UV active, petroleum ether 40/60:diethyl ether 1:1). 
1H NMR (300 MHz, CDCl3) δH 10.34 (s, 1H,) 6.96 (d, J = 9.1 Hz, 1H), 6.86 (d, J = 9.1 
Hz, 1H), 3.82 (s, 3H,), 3.81 (s, 3H).  
13C NMR (101 MHz, CDCl3) δC 191.00, 155.48, 150.47, 124.76, 117.20, 114.71, 111.52, 
57.24, 56.66. 
HRMS (pNSI): calculated for C9H9BrO3: [M+H]
+: 246.9787; observed: 246.9786.  
IR (neat): υ max/cm-1 2930, 2837, 1689. 
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(E)-4-(2-Bromo-3,6-dimethoxyphenyl)but-3-en-2-one 3.36 
 
In a Schlenk flask, 2-bromo-3,6-dimethoxybenzaldehyde 3.19 (1 g, 4.10 mmol) and 1-
(triphenylphosphoranylidene)propan-2-one 2.31 (1.439 g, 4.55 mmol) were dissolved in DCM 
(25 mL). The mixture was refluxed for 60 hours. The resulting reaction mixture was cooled, 
filtered and the solvent was removed under reduced pressure. The resulting crude material was 
purified by silica gel (petroleum ether 40/60:diethyl ether 1:1) to give 3.36 (1.123 g, 3.93 
mmol, 94 %) as a pale yellow powder.  
mp 110-112 oC. 
Rf  0.275 (UV active, petroleum ether 40/60:diethyl ether 1:1). 
1H NMR (300 MHz, CDCl3) δH 7.85 (d, J = 16.5 Hz, 1H), 7.04 (d, J = 16.5 Hz, 1H), 6.91 (d, 
J = 9.1 Hz, 1H), 6.87 (d, J = 9.1 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 2.42 (s, 3H).  
13C NMR (101 MHz, CDCl3) δC 199.72, 153.62, 150.53, 139.28, 133.70, 124.61, 116.79, 
113.12, 110.44, 57.01, 56.13, 27.03.  
HRMS (pNSI): calculated for C12H14Br1O3 [M+H]
+: 286.0155; observed: 286.0154.  
IR (neat): υ max/cm-1 2998, 2836, 1565, 1253. 
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(E)-2-(2-Bromo-3,6-dimethoxystyryl)-2-methyl-1,3-dioxolane 3.37 
 
Into a 50 cm3 round bottomed flask, (E)-4-(2-bromo-3,6-dimethoxyphenyl)but-3-en-2-one 
3.36 (44.7 mg, 0.16 mmol) was dissolved in toluene (5 mL). p-Toluenesulfonic acid 
monohydrate (3.00 mg, 0.01 mmol) and ethylene glycol (0.043 mL, 0.78 mmol) were added 
then the mixture was refluxed for 4 hours in a Dean-Stark apparatus. The reaction mixture was 
allowed to cool to room, diluted with DCM (10 mL), washed with a saturated solution of 
Na2CO3 (2×15 mL). The combined organics were washed with brine (15 mL), dried over 
MgSO4, filtered and the solvent was removed under reduced pressure. The resulting crude 
material was purified by silica gel chromatography (petroleum ether 40/60:diethyl ether 7:3) 
to give 3.37 (5 mg, 0.02 mmol, 13%) as a colourless oil. 
Rf  0.4 (UV active, petroleum ether 40/60 : diethyl ether 1:1).  
1H NMR (300 MHz, CDCl3) δH 6.89 (d, J = 16.5 Hz, 1H), 6.81 (d, J = 7.0 Hz, 2H), 6.36 (d, J 
= 16.5 Hz, 1H), 4.04 (m, J = 0.9 Hz, 4H), 3.87 (s, 3H), 3.81 (s, 3H), 1.61 (s, 3H). 
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(E)-4-(2-Bromo-3,6-dimethoxyphenyl)but-3-en-2-ol 3.38 
 
In a Schlenk flask, (E)-4-(2-bromo-3,6-dimethoxyphenyl)but-3-en-2-one 3.36 (0.558 g, 1.94 
mmol) was dissolved in toluene (10 mL). At -78 oC, diisobutylaluminum hydride solution 
(0.42 mL, 1.0 M in toluene, 0.42 mmol) was added dropwised to the solution and then the 
reaction was allowed to stir for 3 hours. The reaction was poured into a mixture of ice and 
saturated solution of NH4Cl (10 mL). The phases were separated, and the aqueous layer was 
washed with DCM (2×10 mL). The combined organic extracts were washed with brine (25 
mL), dried over MgSO4, filtered and the solvent was removed under reduced pressure. The 
residue was purified by silica gel column chromatography (petroleum ether 40/60: diethyl 
ether 1:1) to produce 3.38 (0.526 mg, 1.83 mmol, 94%) as a white crystalline powder. 
mp 69.5-71oC.  
Rf 0.475 (UV active, petroleum ether 40/60:diethyl ether 1:2). 
1H NMR (300 MHz, CDCl3) δH 6.84 (d, J = 9.1 Hz, 1H), 6.78 (d, J = 9.1 Hz, 1H), 6.72 (d,  J 
= 16.1, 1H), 6.52 (dd, J = 16.1, 6.3 Hz, 1H), 4.53 (dq, J = 6.4, 1.1 Hz, 1H), 3.87 (s, 3H), 3.82 
(s, 3H), 1.41 (d, J = 1.1 Hz, 3H).  
13C NMR (101 MHz, CDCl3) δC 152.47, 150.47, 140.83, 127.21, 124.37, 115.08, 110.85, 
110.43, 69.65, 56.89, 56.24, 23.26. 
HRMS (pNSI): calculated for C12 H15 BrO3 Na: [M+Na]
+: 311.0075; observed: 311.0076. 
IR (neat): υ max/cm-1 3382, 2968, 1565. 
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(E)-4-(2-Bromo-3,6-dimethoxyphenyl)but-3-en-2-ol 3.39 
 
In a Schlenk flask, (E)-4-(2-bromo-3,6-dimethoxyphenyl)but-3-en-2-one 3.36 (76.4 mg, 0.18 
mmol) was dissolved in toluene (10 mL). At -78 oC, diisobutylaluminum hydride solution 
(0.032 mL, 1.0 M in toluene, 0.03 mmol) was added dropwised to the solution then the reaction 
was allowed to stir for 3 hours. The reaction was poured into a mixture of cold methanol (10 
mL) and 1.0 M of HCl (10 mL). The phases were separated, and the aqueous layer was washed 
with DCM (2×10 mL). The combined organic extracts were washed with brine (25 mL), dried 
over MgSO4, filtered and the solvent was removed under reduced pressure. The crude reaction 
material was purified by silica gel column chromatography (petroleum ether 40/60:diethyl 
ether 1:1) to afford titled compound (30.50 mg, 0.10 mmol, 38%) as colourless crystals. 
mp 80.5-82 oC. 
Rf  0.6 (UV active, petroleum ether 40/60:diethyl ether 1:1).  
1H NMR (300 MHz, CDCl3) δH 6.84 (d, J = 9.1 Hz, 1H), 6.79 (d, J = 9.1 Hz, 1H), 6.72 (d, J 
= 16.1 Hz, 1H), 6.52 (dd, J = 16.1, 6.3 Hz, 1H), 4.53 (m, J = 6.3, 1.1 Hz, 1H), 3.87 (s, 3H), 
3.82 (s, 3H), 1.41 (d, J = 1.1 Hz, 3H).  
13C NMR (101 MHz, CDCl3) δC 152.60, 150.51, 138.77, 127.47, 126.54, 115.01, 110.57, 
110.52, 79.03, 56.97, 56.38, 56.24, 21.62.  
HRMS (pNSI): calculated for C13 H17 BrO3 Na [M+Na]
+: 323.0253; observed: 323.0253. 
IR (neat): υ max/cm-1 2835, 1569, 1474. 
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(±)-2,2-Dimethyl-1,3-dioxolane-4-carbaldehyde 4.13 
 
In a Schlenk flask, oxalyl chloride (0.5 mL, 5.50 mmol) was dissolved in DCM (3 mL). At -
78 °C, a solution of methyl sulfoxide (0.9 mL, 12.0 mmol) in DCM (5 mL) was added. The 
reaction mixture was allowed to stir for 15 minutes. (±)-(2,2-Dimethyl-1,3-dioxolan-4-
yl)methanol 4.14 (0.6 mL, 5.00 mmol) was added then the reaction was stirred for additional 
15 minutes at -78 °C. Triethylamine (3.5 mL, 25.0 mmol) was added and the reaction was 
warmed to room temperature. The reaction was quenched with an aqueous solution of NH4Cl 
(10 mL), the phases were separated, and the aqueous layer was extracted with DCM (2×10 
mL). The combined organic extracts were washed with brine (20 mL), dried over MgSO4, 
filtered and the solvent was removed under reduced pressure. The resulting residue was 
purified by silica gel column chromatography (petroleum ether 40/60:diethyl ether 2:1) to 
produce 4.13 (0.110 g, 0.84 mmol, 17%) as a colourless oil. 
Rf  0.4 (UV active, petroleum ether 40/60: ethyl acetate 3:2).
  
1H NMR (300 MHz, CDCl3) δH 9.75 (d, J = 1.9 Hz, 1H, C4H), 4.41 (ddd, J = 7.1, 4.8, 1.9 Hz, 
1H, C3H), 4.20 (d, J = 8.8, 7.1 Hz, 1H, C1H), 4.13 (dd, J = 8.8, 4.8 Hz, 1H, C1H), 1.51 (s, 3H, 
CH3), 1.44 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δC 201.95 (C4), 111.36 (C2), 79.92 (C3), 65.66 (C1), 26.32 (C2-
CH3), 25.21 (C
2-CH3). 
HRMS (pNSI): calculated for C6H10O3: [M+H]
+: 131.0703; observed: 131.0702. 
IR (neat): υ max/cm-1 3326, 2980, 1381. 
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1,2:5,6-Di-O-isopropylidene-D-mannitol 4.21 
 
In a Schlenk flask, at 0 °C, D-mannitol 4.22 (1.821 g, 10.0 mmol) was added to a suspension  
of zinc chloride (2.896 g, 21.3 mmol) in acetone (18 mL), then the reaction was warmed to 
room temperature. After 24 hours, potassium carbonate (3.109 g, 22.5 mmol) was added then 
the reaction was vigorously stirred at 0 °C. The resulting suspension was filtered, extracted 
with ethyl acetate (2×4 mL), and the organic filtrate was washed with water (15 ml). The 
combined organic layers were washed with saturated solution of NaHCO3 and brine (25 mL), 
dried over Na2SO4 and the solvents was removed under reduced pressure. The desired product 
4.21 was recrystallized from cyclohexane (1.2525 g, 4.78 mmol, 48 %) as white crystals. 
mp 120-121.5 oC. (lit.119.5-121 oC).113 
Rf  0.3 (UV active, petroleum ether 40/60:ethyl acetate 2:3).
  
1H NMR (300 MHz, CDCl3) δH 4.27 – 4.11 (m, 4H), 3.99 (dd, J = 8.4, 5.5 Hz, 2H), 3.77 (t, J 
= 6.2 Hz, 2H), 2.58 (d, J = 6.6 Hz, 2H), 1.44 (s, 6H), 1.38 (s, 6H). 
13C NMR (101 MHz, CDCl3) δC 109.47, 76.37, 71.28, 66.81, 26.80, 25.27. 
HRMS (pNSI): calculated for C12H22O6: [M-H]
-:261.1344; observed: 261.1340.  
IR (neat): υ max/cm-1 3388, 2980, 1381. 
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(R)-(-)-2,2-Dimethyl-1,3-dioxolane-4-carbaldehyde (R)-4.13 
 
In a Schlenk flask, 1,2:5,6-Di-O-isopropylidene-D-mannitol 4.21 (1.242 g, 4.73 mmol) and 
sodium periodate (2.026 g, 9.47 mmol) were dissolved in DCM (10 mL). Saturated aqueous 
solution of sodium bicarbonate (0.51 mL) was added then the reaction was allowed to stir for 
2 hours at room temperature. Next, Na2SO4 was added then the reaction was stirred for 5 
minutes. The reaction mixture was filtered through a sintered glass to a pre-weighted round 
bottomed flask then the residue was washed with DCM (2×4 mL). The desired product (R)-
4.13 was obtained from DCM using a short bath distillation at 40 °C under atmospheric 
pressure (1.230 g, 9.45 mmol, 99%) as a colourless oil. 
Rf  0.4 (UV active, petroleum ether 40/60: ethyl acetate 3:2).
  
1H NMR (300 MHz, CDCl3) δH 9.75 (d, J = 1.9 Hz, 1H, C4H), 4.41 (ddd, J = 7.1, 4.8, 1.9 Hz, 
1H, C3H), 4.20 (d, J = 8.8, 7.1 Hz, 1H, C1H), 4.13 (dd, J = 8.8, 4.8 Hz, 1H, C1H), 1.51 (s, 3H, 
CH3), 1.44 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δC 201.95 (C4), 111.36 (C2), 79.92 (C3), 65.66 (C1), 26.32 (C2-
CH3), 25.21 (C
2-CH3). 
HRMS (pNSI): calculated for C6H10O3: [M+H]
+: 131.0703; observed: 131.0702. 
IR (neat): υ max/cm-1 3326, 2980, 1381. 
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1-(2,2-Dimethyl-1,3-dioxolan-4-yl)but-2-yn-1-ol 4.12 
 
In a Schlenk flask, (R)-(-)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (R)-4.13 (1.224 g, 9.40 
mmol) was dissolved in THF (30 mL). 1-Propynylmagnesium bromide solution 0.5 M in THF 
(37.6 mL, 18.81 mmol) was added at 0 °C then the reaction was warmed to room temperature. 
After 12 hours, the reaction was quenched with a saturated solution of NH4Cl (30 mL) and 
diluted with DCM (30 mL). The organic layer was separated, then the aqueous layer was 
washed with DCM (30 mL). The combined organics were washed with brine (60 mL), dried 
over Na2SO4, filtered and the solvent was removed under reduced pressure. The crude material 
was purified by silica gel column chromatography (3:2 petroleum ether 40/60:diethyl ether) to 
give 4.12 (1 g, 5.87 mmol, 63%) as a brown oil. 
Rf  0.25 (UV active, petroleum ether 40/60:diethyl ether 3:2). 
1H NMR (300 MHz, CDCl3) 
1H NMR (300 MHz,) δH 4.40-3.34 (m, 1H), 4.23 – 3.94 (m, 4H), 
1.79 (d, J = 2.1 Hz, 3H), 1.40 (s, 3H), 1.31 (s, 3H). 
13C NMR (101 MHz, CDCl3) δC 110.30, 82.42, 82.25, 76.98, 66.22, 64.31, 26.67, 26.32, 3.59.  
HRMS (pNSI): calculated for C9H14O3: [M+H]
+: 171.1016; observed: 171.1013. 
IR (neat): υ max/cm-1 3388. 
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1-(2,2-Dimethyl-1,3-dioxolan-4-yl)but-2-yn-1-one 4.11 
 
In a Schlenk flask, oxalyl chloride (0.095 mL, 1.09 mmol) was dissolved in DCM (5 mL). 
DMSO (0.07 mL, 1.00 mmol) was added to the soultion at -78 °C then the reaction was stirred 
for 10 minutes. 1-(2,2-Dimethyl-1,3-dioxolan-4-yl)but-2-yn-1-ol 4.12 (0.155 g, 0.91 mmol) 
was dissolved in DCM (5 mL) and transferred with a cannula to the reaction mixture. After 15 
minutes, triethylamine (0.63 mL, 4.55 mmol) was added and the reaction was stirred for 1.5 
hours at room temperature. The reaction was quenched with ammonium chloride solution (10 
mL). The organic layer was separated and the aqueous layer was washed with DCM (10 mL). 
Combined organic layers were washed with brine (20 mL), dried over Na2SO4 and the solvent 
was removed under reduced pressure to give 4.11 (0.153 g, 1.0 mmol, 100%) as a colourless 
oil. 
Rf  0.3 (UV active, petroleum ether 40/60:diethyl ether 3:2).  
1H NMR (300 MHz, CDCl3) δH 4.47 (dd, J = 7.4, 5.0 Hz, 1H), 4.18 (dd, J = 8.8, 7.4 Hz, 1H), 
4.09 (dd, J = 8.8, 5.0 Hz, 1H), 2.02 (s, 3H), 1.45 (d, J = 0.8 Hz, 3H), 1.35 (s, 3H). 
13C NMR (101 MHz, CDCl3) δC 186.75, 111.78, 95.42, 80.99, 78.34, 66.78, 26.11, 25.49, 
4.47.  
HRMS (pNSI): calculated for C9H12O3: [M+H]
+: 169.0859 ; observed: 169.0856.  
IR (neat): υ max/cm-1 2989, 1671. 
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Ethyl 2-hydroxy-4-oxopentanoate 4.16 
 
Acetone 4.18 (2 mL, 43.5 mmol), Ethyl glyoxalate solution ~50% in toluene 4.17 (0.86 mL, 
8.70 mmol) and water (0.2 mL) were added in a round bottomed flask 50 cm3. Pyrrolidine (0.2 
mL, 2.64 mmol) was added then the reaction was stirred for 12 hours at room temperature. The 
reaction mixture was diluted with DCM (10 mL). The separated organic layer was washed 
with water (2×10 mL) and brine (10 mL), dried over Na2SO4 and the solvent was removed 
under reduced pressure. The resulting crude material was purified by silica gel column 
chromatography (ethyl acetate: petroleum ether 40/60 2:1) to give 4.16 (0.195 g, 1.21 mmol, 
14%) as a colourless oil. 
Rf  0.3 (UV active, petroleum ether 40/60:ethyl acetate 1:2).  
1H NMR (300 MHz, CDCl3) δH 4.52 – 4.41 (m, 1H, C2H), 4.24 (q, J = 7.1 Hz, 2H, C1'H), 2.98 
(dd, J = 17.4, 4.1 Hz, 1H, C3H), 2.89 (dd, J = 17.4, 6.3 Hz, 1H, C3H), 2.20 (s, 3H, C5H), 1.28 
(t, J = 7.1 Hz, 2H, C2'H). 
13C NMR (101 MHz, CDCl3) δC 206.32 (C4), 173.72 (C1), 66.98 (C2), 61.95 (C1'), 46.87 (C3), 
30.58 (C5), 14.17 (C2').  
HRMS (pNSI): calculated for C7H12O4: [M+H]
+: 161.0808 ; observed: 161.0804.  
IR (neat): υ max/cm-1 3433, 1715. 
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(2-Bromo-3,6-dimethoxyphenyl)methanol 4.24 
 
In a Schlenk flask, 2-bromo-3,6-dimethoxtbenzaldehyde 3.19 (0.550 g, 2.26 mmol) was 
dissolved in toluene (20 mL). At -78 oC, diisobutylaluminum hydride solution (3.40 mL, 1.0 
M in toluene, 3.40 mmol) was added dropwised to the solution and the reaction was allowed 
to stir for 3 hours. The reaction was poured into a mixture of ice and a saturated solution of 
ammonium chloride (20 mL). The phases were separated, and the aqueous layer was washed 
with DCM (2×20 mL). The combined organic extracts were washed with brine (40 mL), dried 
over MgSO4, filtered and the solvent was removed under reduced pressure to provide 4.24 
(0.54 g, 2.18 mmol, 97%) as a white crystalline powder. 
mp 124-125.5 oC (lit. 127-128°C).114  
Rf  0.25 (UV active, petroleum ether 40/60:diethyl ether 1:1).  
1H NMR (300 MHz, CDCl3) δH 6.85 (s, 2H), 4.94 (s, 2H), 3.88 (s, 3H), 3.86 (s, 3H). 
13C NMR (101 MHz, CDCl3) δC 152.72, 150.44, 130.05, 115.21, 111.71, 110.12, 60.66, 56.98, 
56.36.  
HRMS (pNSI): calculated for C9H10 BrO2: [M-OH]
+: 230.9838; observed: 230.9837.  
IR (neat): υ max/cm-1 3272. 
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((2-Bromo-3,6-dimethoxybenzyl)oxy)(tert-butyl)dimethylsilane 4.23 
 
In a Schlenk flask, imidazole (0.983 g, 14.5 mmol and tert-butyldimethylsilyl chloride (2.179 
g, 14.4 mmol) were dissolved in DCM (25 mL) then (2-bromo-3,6-dimethoxyphenyl)methanol 
4.24 (1.19 g, 4.82 mmol) was added. The reaction was stirred for 12 hours at room temperature. 
The reaction mixture was washed with water (25 mL) and extracted with DCM (25 mL). 
Combined organic extracts washed with brine (30 mL), dried over MgSO4 and the solvent was 
removed under reduced pressure. The resulting crude material was purified with silica gel 
column chromatography (petroleum ether 40/60:diethyl ether 1:2 to give 4.23 (0.404 g, 1.10 
mmol, 98%) as a white powder. 
mp 73-75°C. 
Rf  0.4 (UV active, petroleum ether 40/60:diethyl ether 1:2).  
1H NMR (400 MHz, CDCl3) δH 6.80 (s, 2H), 4.87 (s, 2H), 3.83 (s, 3H), 3.79 (s, 3H), 0.90 (s, 
9H), 0.09 (s, 6H).  
13C NMR (101 MHz, CDCl3) δC 152.93, 150.55, 130.42, 116.56, 111.75, 110.84, 59.87, 56.93, 
56.75, 26.10, 18.69, -5.09.  
HRMS (pNSI): calculated for C15H25BrO3Si: [M+Na]
+: 384.0674; observed: 384.0683.  
IR (neat): υ max/cm-1 2971, 1255. 
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2-(((tert-butyldimethylsilyl)oxy)methyl)-3,6-dimethoxybenzaldehyde 4.5 
 
In a Schlenk flask, ((2-bromo-3,6-dimethoxybenzyl)oxy)(tert-butyl)dimethylsilane 4.23 
(0.824 g, 2.28 mmol) was dissolved in THF (20 mL). At -78 °C n-butyllithium 2.5 M in hexane 
(1.36 mL, 3.42 mmol) was added dropwise and the reaction was stirred for 30 minutes. N,N-
dimethylformamide (0.9 mL, 11.4 mmol) was added then the reaction was stirred for additional 
30 minutes at room temperature. The reaction was quenched with cold water (20 mL). The 
aqueous layer was washed with DCM (2×20 mL). The combined organic extracts were washed 
with brine (40 mL), dried over MgSO4 and the solvent was removed under reduced pressure. 
The resulting crude material was purified by silica gel column chromatography (petroleum 
ether 40/60:diethyl ether 7:3) to give 4.5 (0.29 g, 0.96 mmol, 42%) as colourless crystals. 
mp 58.5-61 °C. 
Rf  0.425 (UV active, petroleum ether 40/60:diethyl ether 7:3). 
1H NMR (400 MHz, CDCl3) δH 10.51 (s, 1H), 7.01 (d, J = 9.1 Hz, 1H), 6.87 (d, J = 9.1 Hz, 
1H), 4.98 (s, 2H), 3.83 (s, 3H), 3.80 (s, 3H), 0.87 (s, 9H), 0.06 (s, 6H). 
13C NMR (101 MHz, CDCl3) δC 192.86, 155.04, 151.43, 131.34, 125.60, 116.90, 111.74, 
56.84, 56.37, 55.40, 26.03, 18.57, -5.27.  
HRMS (pNSI): calculated for C16H26O4: [M+H]
+: 283.1724; observed: 283.1727.  
IR (neat): υ max/cm-1 2928, 1651, 1462. 
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(2-(tert-butyldimethylsilyl)-3,6-dimethoxyphenyl)methanol 5.13 
 
In a Schlenk flask, ((2-bromo-3,6-dimethoxybenzyl)oxy)(tert-butyl)dimethylsilane 4.23 
(0.120 g, 0.33 mmol) was dissolved in THF (10 mL). At -78 °C, n-butyllithium 2.5 M in hexane 
(0.14 mL, 0.34 mmol) was added dropwise and the reaction was stirred for 25 minutes. 
Propylene oxide (0.04 mL, 0.50 mmol) was then added and the reaction was stirred for 2 hours 
at room temperature. The reaction was quenched with cold water (15 mL) and the product was 
extracted with DCM (2×15 mL). Combined organic extracts were washed with brine (30 mL), 
dried over MgSO4 and the solvent was removed under reduced pressure. The resulting crude 
was purified by silica gel column chromatography (petroleum ether 40/60:diethyl ether 3:2) to 
give 5.13 (92.4 mg, 0.33 mmol, 99%) as a white powder. 
mp 63.5-65 °C.  
Rf  0.3 (UV active, petroleum ether 40/60:diethyl ether 3:2).  
1H NMR (300 MHz, CDCl3) δH 6.91 (d, J = 9.1 Hz, 1H), 6.77 (d, J = 9.1 Hz, 1H), 4.70 (s, 
2H), 3.87 (s, 3H), 3.71 (s, 3H), 0.94 (s, 9H), 0.40 (s, 6H). 
13C NMR (101 MHz, CDCl3) δC 158.96, 152.77, 136.39, 127.09, 112.12, 109.77, 61.37, 55.80, 
55.25, 27.24, 18.29, 0.09. 
HRMS (pNSI): calculated for C16H26O4: [M+Na]
+: 305.1543; observed: 305.1544.  
IR (neat): υ max/cm-1 3591. 
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((2-Bromo-3,6-dimethoxybenzyl)oxy)triisopropylsilane 5.17 
 
In a Schlenk flask, imidazole (0.408 g, 6 mmol), triisopropylsilyl chloride (1.27mL, 6 mmol) 
and (2-bromo-3,6-dimethoxyphenyl)methanol 4.24 (0.494 g, 2 mmol) were dissolved in DCM 
(15 mL). The reaction was stirred for 18 hours at room temperature. The reaction mixture was 
washed with water (15 mL) and the product was extracted with DCM (2×15 mL). Combined 
organic extracts was washed with brine (30 mL), dried over MgSO4 and the solvent was 
removed under reduced pressure. The resulting crude product was purified by silica gel column 
chromatography (petroleum ether 40/60:diethyl ether 10:1) to give 5.17 (0.650 g, 1.61 mmol, 
81%) as colourless crystals. 
mp 87-88°C. 
Rf  0.3 (UV active, petroleum ether 40/60:diethyl ether 10:1).  
1H NMR (400 MHz, CDCl3) δH 6.80 (s, 2H), 4.95 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 1.19-1.11 
(m, 3H), 1.09 (s, 18H). 
13C NMR (101 MHz, CDCl3) δC 152.86, 150.44, 130.52, 116.68, 111.61, 110.35, 59.93, 56.92, 
56.34, 18.10, 12.27.  
HRMS (pNSI): calculated for C18H31BrO3Si: [M+H]
+: 403.1299; observed: 403.1300. 
IR (neat): υ max/cm-1 2938, 2864, 1460. 
  
Chapter 6 Experimental Section 
 
 
122 
 
2-(2-Bromo-3,6-dimethoxyphenyl)-1,3-dioxolane 5.21 
 
In a 50 cm3 round bottomed flask, 2-bromo-3,6-dimethoxybenzaldehyde (0.192 g, 0.78 mmol) 
3.19, ethylene glycol (1.30 mL, 23.5 mmol) and p-toluenesulfonic acid monohydrate (29.7 mg, 
0.16 mmol) were dissolved in toluene (10 mL). The reaction was refluxed for 4 hours. The 
reaction mixture was washed with water (10 mL) and the organic layer was extracted with 
DCM (2×10 mL). Combined organic layers washed with brine (20 mL), dried over Mg2SO4 
and the solvent was removed under reduced pressure. The resulting crude material was purified 
by silica gel column chromatography (petroleum ether 40/60:diethyl ether: 1:2) to give 5.21 
(0.180 g, 0.62 mmol, 80%) as a pale yellow oil. 
Rf  0.3 (UV active, petroleum ether 40/60:diethyl ether 2:1). 
1H NMR (300 MHz, CDCl3) δH 6.91 (d, J = 9.1 Hz, 1H), 6.87 (d, J = 9.1 Hz, 1H), 6.53 (s, 
1H), 4.35 – 4.22 (m, 2H), 4.10 – 4.03 (m, 2H), 3.85 (s, 3H), 3.82 (s, 3H).  
13C NMR (101 MHz, CDCl3) δC 153.90, 150.68, 125.36, 117.20, 113.53, 111.77, 101.99, 
66.12, 57.18, 56.94.  
HRMS (pNSI): calculated for C11H13BrO4: [M+H]
+: 290.0104; observed: 290.0101.  
IR (neat): υ max/cm-1 2868, 2837, 1481. 
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2-Bromo-3-(dimethoxymethyl)-1,4-dimethoxybenzene 5.23 
 
In a 50 cm3 round bottomed flask, 2-bromo-3,6-dimethoxtbenzaldehyde 3.19 (0.267 g, 1.09 
mmol) and p-toluenesulfonic acid monohydrate (36 mg, 0.108 mmol) were dissolved in 
methanol (10 mL). Trimethyl orthoformate (1.19 mL, 10.89 mmol) was added then the reaction 
was allowed to stir for 12 hours at room temperature. The reaction mixture was washed with 
water (20 mL), and the aqueous layer was washed with DCM (2×20 mL). The combined 
organic extracts were washed with brine (40 mL), dried over MgSO4, filtered and the solvent 
was removed to give 5.23 (0.315 g, 1.01 mmol, 99%) as a white crystalline powder.  
mp 75-77.5 oC. 
Rf  0.25 (UV active, petroleum ether 40/60:diethyl ether 1:1).  
1H NMR (400 MHz, CDCl3) δH 6.85 (d, J = 9.1 Hz, 1H, C6-H), 6.84 (d, J = 9.1 Hz, 1H, C5-
H), 5.85 (s, 1H, O-CH-O), 3.83 (s, 3H, Ar-OCH3), 3.81 (s, 3H, Ar-OCH3), 3.47 (s, 3H, CH-
OCH3), 3.46 (s, 3H, CH-OCH3).  
13C NMR (101 MHz, CDCl3) δC 153.09 (C1), 150.58 (C4), 127.15 (C-Ar), 114.08 (C-Ar), 
112.59 (C-Ar), 111.98 (C-Ar), 105.08 (O-CH-O), 57.19 (Ar-OCH3), 57.10 (Ar-OCH3), 56.20 
(CH-OCH3), 53.52 (CH-OCH3). 
HRMS (pNSI): calculated for C11H15 BrO4: [M-OH]
+: 230.9838; observed: 230.9837. 
IR (neat): υ max/cm-1 2931, 2837, 1687. 
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1-(2-(Dimethoxymethyl)-3,6-dimethoxyphenyl)propan-2-ol 5.24 
 
In a Schlenk flask, 2-bromo-3-(dimethoxymethyl)-1,4-dimethoxybenzene 5.23 (0.501 g, 1.75 
mmol) was dissolved in THF (20 mL). n-Butyllithium (0.84 mL, 2.11 mmol) was added 
dropwise and the reaction was stirred at -78 °C for 20 minutes. Propylene oxide (1.2 mL, 17.5 
mmol) was added and the reaction was stirred for 30 hours. The reaction was quenched with 
saturated solution of NH4Cl (20 mL) and the product was extracted with DCM (2×20 mL). 
Combined organic extracts were washed with brine (40 mL), dried over Na2SO4 and the solvent 
was removed under reduced pressure. The resulting crude material was purified by silica gel 
column chromatography (0.138 g, 0.61 mmol, 36%) as a white powder. 
mp 83-85 °C. 
Rf  0.5 (UV active, petroleum ether 40:60 /ether, 1:1).  
1H NMR (300 MHz, CDCl3) δH 6.83 (d, J = 9.1 Hz, 1H), 6.75 (d, J = 9.1 Hz, 1H), 4.24 (ddq, 
9.6, 6.1, 2.8 Hz, 1H), 3.79 (s, 6H), 3.55 (s, 3H), 3.39 (s, 3H), 3.21 (dd, J = 13.8, 9.6 Hz, 1H), 
3.04 (dd, J = 13.8, 2.8 Hz, 1H), 1.31 (d, J = 6.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δC 150.95, 150.61, 124.78, 123.79, 109.82, 108.35, 95.37, 62.04, 
56.20, 55.78, 55.29, 50.86, 29.99, 21.48.  
HRMS (pNSI): calculated for C14H22O5: [M+Na]
+: 293.1359; observed: 293.1358.  
IR (neat): υ max/cm-1 3354, 2904. 
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5,8-Dimethoxy-3-methylisochroman-1-ol 5.25 
 
In a round bottomed flask 50 cm3, 1-(2-(dimethoxymethyl)-3,6-dimethoxyphenyl)propan-2-ol 
5.24 (170 mg, 0.63 mmol) was dissolved in DCM (5 mL) followed by the addition of water 
(0.12 mL, 6.28 mmol). Trifluoroacetic acid (0.2 mL, 1.66 mmol) was added then the reaction 
was stirred for 30 minutes at room temperature. The reaction was washed with an aqueous 
solution of NaHCO3 (2×10 mL). Combined organic layers were washed with brine (20 mL), 
dried over Na2SO4 and the solvent was removed under reduced pressure. The resulting crude 
material was purified by silica gel column chromatography (UV active, petroleum ether 40/60: 
diethyl ether 1:1) to give 5.25 (39 mg, 0.18 mmol, 28%) as a mixture of colourless oil and 
crystals.  
Rf  0.275 (UV active, petroleum ether 40/60:diethyl ether 1:1). 
1H NMR (300 MHz, CDCl3) δH 6.83 (d, J = 9.1 Hz, 1H), 6.75 (d, J = 9.1 Hz, 1H), 5.88 
(s, 1H), 4.02 (ddq, J = 9.6, 6.1, 2.8 Hz, 1H), 3.79 (s, 6H), 3.55 (s, 3H), 3.39 (s, 3H), 3.21 
(dd, J = 13.8, 9.6 Hz, 1H), 3.04 (dd, J = 13.8, 2.8 Hz, 1H), 1.30 (d, J = 6.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δC 150.89, 149.09, 126.40, 123.88, 108.05, 107.21, 69.01, 63.05, 
55.62, 47.59, 29.78, 21.74. 
IR (neat): υ max/cm-1 3421. 
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5,8-Dimethoxy-3-methylisochroman-1-ol 5.25 
 
In a round bottomed flask 50 cm3, 1-(2-(dimethoxymethyl)-3,6-dimethoxyphenyl)propan-2-ol 
5.24 (60 mg, 0.22 mmol) was dissolved in acetone (5 mL). Iodine was added (5.63 mg, 0.02 
mmol) and the reaction was stirred for 45 minutes at room temperature. The reaction was 
quenched with an aqueous solution of Na2S2O3 (10 mL) and the product was extracted with 
DCM (2×10 mL). Combined organic extracts were washed with brine (20 mL), dried over 
Na2SO4 and the solvent was removed under reduced pressure. The resulting crude material 
was purified by silica gel column chromatography (UV active, petroleum ether 40/60:diethyl 
ether 1:1) to give 5.25 (85 mg, 0.19 mmol, 89%) as a mixture of colourless oil and crystals.  
Rf  0.275 (UV active, petroleum ether 40/60:diethyl ether 1:1). 
1H NMR (300 MHz, CDCl3) δH 6.83 (d, J = 9.1 Hz, 1H), 6.75 (d, J = 9.1 Hz, 1H), 5.88 
(s, 1H), 4.02 (ddq, J = 9.6, 6.1, 2.8 Hz, 1H), 3.79 (s, 6H), 3.55 (s, 3H), 3.39 (s, 3H), 3.21 
(dd, J = 13.8, 9.6 Hz, 1H), 3.04 (dd, J = 13.8, 2.8 Hz, 1H), 1.30 (d, J = 6.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δC 150.89, 149.09, 126.40, 123.88, 108.05, 107.21, 69.01, 63.05, 
55.62, 47.59, 29.78, 21.74. 
IR (neat): υ max/cm-1 3419. 
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2-Bromo-1,4-dimethoxy-3-(methoxymethyl)benzene 5.28 
 
In a Schlenk flask, (2-bromo-3,6-dimethoxyphenyl)methanol 4.24 (0.121 g, 0.49 mmol) and 
NaH 60% in mineral oil (39.16 mg, 0.98 mmol) were dissolved in THF (10 mL). Methyl iodide 
(0.60 mL, 0.98 mmol) was added and the reaction was stirred for 12 hours at room temperature. 
The reaction was quenched with water (15 mL) and the product was extracted with DCM (2×15 
mL). Combined organic extracts were washed with brine (25 mL), dried over Na2SO4, filtered 
and the solvent was removed under reduced pressure. The resulting crude product was purified 
by silica gel column chromatography (petroleum ether 40/60:diethyl ether 1:2) to give 5.28 
(0.112 g, 0.43 mmol, 88%) as a white crystalline powder.  
mp 61-62.5 °C.  
Rf  0.5 (UV active, petroleum ether 40:60 /ether, 1:1).  
1H NMR (300 MHz, CDCl3) δH 6.79 (d, J = 9.1 Hz, 1H), 6.74 (d, J = 9.1 Hz, 1H), 4.62 (s, 
2H), 3.77 (s, 3H), 3.74 (s, 3H), 3.35 (s, 3H). 
13C NMR (101 MHz, CDCl3) δC 153.32, 150.46, 127.45, 117.12, 112.40, 110.37, 68.20, 58.50, 
57.02, 56.64.  
HRMS (pNSI): calculated for C14H22O5: [M+NH4]
+: 278.0386; observed: 278.0383. 
IR (neat): υ max/cm-1 2970, 2837, 1065. 
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1-(3,6-Dimethoxy-2-(methoxymethyl)phenyl)propan-2-ol 5.29 
 
In a Schlenk flask, 2-bromo-1,4-dimethoxy-3-(methoxymethyl)benzene 5.28 (0.466g, 1.78 
mmol) was dissolved in THF (20 mL). n-Butyllithium (1.1 mL, 2.67 mmol) was added 
dropwise at -78 °C then the reaction was stirred for 20 minutes. Propylene oxide (0.6 mL, 8.92 
mmol) was added then the reaction was warmed to room temperature. After 4 hours, the 
reaction was quenched with a saturated solution of NH4Cl (20 mL). The aqueous layer was 
washed with DCM (2×20 mL) and the combined organic extracts were washed with brine (20 
mL), dried over MgSO4 and solvent was removed under reduced pressure. The crude reaction 
mixture was purified by silica gel column chromatography (petroleum ether 40/60:diethyl 
ether 1:2) to give 5.29 (0.335 g, 1.39 mmol, 78%) as colourless crystals. 
mp 58.5-61 °C. 
Rf  0.3 (UV active, petroleum ether 40/60:diethyl ether 1:2).  
1H NMR (400 MHz, CDCl3) δH 6.80 (d, J = 9.1 Hz, 1H, C4'H), 6.74 (d, J = 9.1 Hz, 1H, C5'H), 
4.72 (d, J = 10.2 Hz, 1H, H2C-OCH3), 4.39 (d, J = 10.2 Hz, 1H, H2C-OCH3), 3.97 (ddq, J = 
9.6, 6.1, 2.8 Hz, 1H, C2H), 3.78 (s, 3H, Ar-OCH3), 3.77 (s, 3H, Ar-OCH3), 3.41 (s, 3H,CH2- 
OCH3), 3.02 (dd, J = 13.8, 2.8 Hz, 1H, C3H), 2.63 (dd, J = 13.8, 9.6 Hz, 1H, C3H), 1.28 (d, J 
= 6.1 Hz, 3H, C1H). 
13C NMR (101 MHz, CDCl3) δC 152.24 (C3'), 152.17 (C6'), 129.99 (C-Ar), 125.96 (C-Ar), 
110.98 (C-Ar), 109.28 (C-Ar), 67.38 (H2C-OCH3), 64.90 (C2), 58.21 (Ar-OCH3), 56.33 (Ar-
OCH3), 55.85 (H2C-OCH3), 36.54 (C3), 24.58 (C1). 
HRMS (pNSI): calculated for C13H21O4: [M+H]
+: 241.1434; observed: 241.1428. 
IR (neat): υ max/cm-1 3422, 2932. 
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5,8-Dimethoxy-3-methylisochromane 5.31 
 
In a Schlenk flask, 1-(3,6-dimethoxy-2-(methoxymethyl)phenyl)propan-2-ol 5.29 (50 mg, 
0.21 mmol) was dissolved in DCM (5 mL). Boron tribromide solution 1.0 M in hexane (0.2 
mL, 0.23 mmol) was added at -78 °C. After 30 minutes the reaction was quenched into a 
mixture of ice and water (10 mL). The product was extracted with DCM (2×10 mL) and the 
combined organic extracts were washed with brine (25 mL), dried over MgSO4 and the solvent 
was removed under reduced pressure to give 5.31 (43 mg, 0.206 mmol, 99%) as a dark red oil.  
Rf  0.35 (UV , petroleum ether 40/60:diethyl ether 1:1).  
1H NMR (300 MHz, CDCl3) δH 6.85 (d, J = 9.1 Hz, 1H), 6.76 (d, J = 9.1 Hz, 1H), 4.76 (d, J 
= 9.7 Hz, 1H), 4.70 (d, J = 9.7 Hz, 1H), 4.10 (dqd, J = 9.6, 6.2, 2.8 Hz, 1H), 3.87 (s, 3H), 3.81 
(s, 3H), 2.99 (dd, J = 13.9, 2.8 1H), 2.91 (dd, J = 13.9, 9.6 Hz, 1H), 1.32 (d, J = 6.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δC 152.14, 151.95, 128.30, 126.61, 111.47, 109.52, 68.34, 56.25, 
55.98, 35.83, 26.32, 23.89.  
HRMS (pNSI): calculated for C12H16O3: [M+H]+: 209.1172; observed: 209.1172. 
IR (neat): υ max/cm-1 2931. 
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5,8-Dimethoxy-3-methylisochromane 5.31 
 
In a Schlenk flask, NaI (124.7 mg, 0.83 mmol) was dissolved in acetonitrile (5 mL) and water 
(0.187 mL, 0.01 mmol), and the reaction was stirred for 30 minutes at 40 °C. 
Chlorotrimethylsilane (0.1 mL, 0.832 mmol) was added and the reaction was stirred for 30 
minutes. A solution of 1-(3,6-dimethoxy-2-(methoxymethyl)phenyl)propan-2-ol (50 mg, 0.21 
mmol) 5.29 in acetonitrile (1 mL) was transferred by a cannula to the reaction mixture. After 
2 hours, the reaction was cooled down to room temperature, washed with a saturated solution 
of Na2S2O3 (10 mL) and the product was extracted with DCM (2×10 mL).The combined 
organic extracts were washed with brine (20 mL), dried over MgSO4 and the solvent was 
removed under reduced pressure to give 5.31 (40.4 mg, 0.20 mmol, 97%) as a dark red oil. 
 
Rf  0.35 (UV , petroleum ether 40/60:diethyl ether 1:1).  
1H NMR (300 MHz, CDCl3) δH 6.85 (d, J = 9.1 Hz, 1H), 6.76 (d, J = 9.1 Hz, 1H), 4.76 (d, J 
= 9.7 Hz, 1H), 4.70 (d, J = 9.7 Hz, 1H), 4.10 (dqd, J = 9.6, 6.2, 2.8 Hz, 1H), 3.87 (s, 3H), 3.81 
(s, 3H), 2.99 (dd, J = 13.9, 2.8 1H), 2.91 (dd, J = 13.9, 9.6 Hz, 1H), 1.32 (d, J = 6.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δC 152.14, 151.95, 128.30, 126.61, 111.47, 109.52, 68.34, 56.25, 
55.98, 35.83, 26.32, 23.89.  
HRMS (pNSI): calculated for C12H16O3: [M+H]+: 209.1172; observed: 209.1172. 
IR (neat): υ max/cm-1 2935. 
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1-(2-(Hydroxymethyl)-3,6-dimethoxyphenyl)propan-2-ol 5.30 
 
In a Schelenk flask, 5,8-dimethoxy-3-methylisochromane 5.31 (43.5 mg, 0.21 mmol) and 
manganese dioxide (0.544 g, 5.26 mmol) were dissolved in DCM (10 mL). The reaction 
mixture was stirred for 12 hours at room temperature. Then, the reaction was filtered and 
the residual solid material was washed with DCM (10 mL) then the solvent was removed 
under reduced pressure. The resulting crude material was purified by silica gel column 
chromatography to give 5.30 (16.3 mg, 0.07 mmol, 34%) as a pale yellow oil. 
Rf  0.5 (UV , petroleum ether 40/60:diethyl ether 1:1).  
1H NMR (400 MHz, CDCl3) δH 6.64 (d, J = 9.1 Hz, 1H), 6.60 (d, J = 9.1 Hz, 1H), 4.91 (d, 
J = 15.9 Hz, 1H), 4.60 (d, J = 15.9 Hz, 1H), 3.77 (s, 3H), 3.75 (s, 3H), 3.70 (ddq, J = 12.2, 
6.1, 3.0 Hz, 1H), 2.76 (dd, J = 17.0, 3.0 Hz, 1H), 2.37 (dd, J = 17.0, 12.2 Hz, 1H), 1.35 (d, 
J = 6.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δC 150.95, 149.53, 124.78, 124.05, 107.50, 106.84, 70.15, 
64.66, 30.39, 21.78. 
IR (neat): υ max/cm-1 3424, 3320. 
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Appendix 
X-ray Crystallography Data 
1,7-dibromo-6H,12H-6,12-epoxydibenzo[b,f][1,5]dioxocine-2,8-diol 3.31 
 
 
Identification code  MJH12 
Chemical formula (moiety) C14H8Br2O5 
Chemical formula (total) C14H8Br2O5 
Formula weight  416.02 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  orthorhombic, Fdd2 
Unit cell parameters a = 21.2980(13) Å  = 90° 
 b = 25.0474(15) Å  = 90° 
 c = 4.8731(4) Å  = 90° 
Cell volume 2599.6(3) Å3 
Z 8 
Calculated density  2.126 g/cm3 
Absorption coefficient  6.256 mm1 
F(000) 1616 
Crystal colour and size colourless, 0.30  0.10  0.10 mm3 
Reflections for cell refinement 1052 ( range 3.2 to 28.4°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.2 to 28.5° 
Index ranges h 22 to 26, k 33 to 30, l 5 to 6 
Completeness to  = 25.0° 99.8%  
Reflections collected 2301 
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Independent reflections 1086 (Rint = 0.0318) 
Reflections with F2>2 1029 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.2555 and 0.5735 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0484, 18.9318 
Data / restraints / parameters 1086 / 1 / 113 
Final R indices [F2>2] R1 = 0.0367, wR2 = 0.0908 
R indices (all data) R1 = 0.0397, wR2 = 0.0929 
Goodness-of-fit on F2 1.099 
Absolute structure parameter  0.01(2) 
Extinction coefficient 0.00040(13) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.75 and 0.53 e Å3 
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(E)-4-(2,5-dimethoxyphenyl)but-3-en-2-one 2.30 
 
 
Identification code  mjh120006 
Chemical formula (moiety) C12H14O3 
Chemical formula (total) C12H14O3 
Formula weight  206.23 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/c1 
Unit cell parameters a = 10.9406(9) Å  = 90° 
 b = 26.6373(16) Å  = 110.058(9)° 
 c = 7.6565(6) Å  = 90° 
Cell volume 2096.0(3) Å3 
Z 8 
Calculated density  1.307 g/cm3 
Absorption coefficient  0.093 mm1 
F(000) 880 
Crystal colour and size colourless, 0.42  0.40  0.05 mm3 
Reflections for cell refinement 3166 ( range 2.8 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 14 to 11, k 32 to 34, l 10 to 10 
Completeness to  = 25.0° 99.8%  
 
 
   Appendix 
 
 
140 
 
Identification code  mjh120006 
Chemical formula (moiety) C12H14O3 
Chemical formula (total) C12H14O3 
Formula weight  206.23 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/c1 
Unit cell parameters a = 10.9406(9) Å  = 90° 
 b = 26.6373(16) Å  = 110.058(9)° 
 c = 7.6565(6) Å  = 90° 
Cell volume 2096.0(3) Å3 
Z 8 
Calculated density  1.307 g/cm3 
Absorption coefficient  0.093 mm1 
F(000) 880 
Crystal colour and size colourless, 0.42  0.40  0.05 mm3 
Reflections for cell refinement 3166 ( range 2.8 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 14 to 11, k 32 to 34, l 10 to 10 
Completeness to  = 25.0° 99.8%  
Reflections collected 12369 
Independent reflections 4473 (Rint = 0.0261) 
Reflections with F2>2 3373 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9619 and 0.9954 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0516, 0.8280 
Data / restraints / parameters 4473 / 0 / 277 
Final R indices [F2>2] R1 = 0.0460, wR2 = 0.1064 
R indices (all data) R1 = 0.0672, wR2 = 0.1208 
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Goodness-of-fit on F2 1.019 
Extinction coefficient 0.0020(7) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.27 and 0.22 e Å3 
  
   Appendix 
 
 
142 
 
1,1'-oxybis(5,8-dimethoxy-3-methylisochromane) 5.27 
 
Identification code  mjh140024_fa  
Empirical formula  C24H30O7  
Formula weight  430.48  
Temperature/K  150.01(10)  
Crystal system  monoclinic  
Space group  I2/a  
a/Å  15.5333(3)  
b/Å  10.87020(17)  
c/Å  26.3068(4)  
α/°  90  
β/°  90.8950(14)  
γ/°  90  
Volume/Å3  4441.36(12)  
Z  8  
ρcalcg/cm3  1.288  
μ/mm-1  0.775  
F(000)  1840.0  
Crystal size/mm3  0.23 × 0.17 × 0.1  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  6.72 to 133.01  
Index ranges  -18 ≤ h ≤ 18, -12 ≤ k ≤ 12, -31 ≤ l ≤ 31  
Reflections collected  58089  
Independent reflections  3905 [Rint = 0.0703, Rsigma = 0.0212]  
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Data/restraints/parameters  3905/249/286  
Goodness-of-fit on F2  1.025  
Final R indexes [I>=2σ (I)]  R1 = 0.0359, wR2 = 0.0874  
Final R indexes [all data]  R1 = 0.0475, wR2 = 0.0955  
Largest diff. peak/hole / e Å-3  0.17/-0.19  
 
 
